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During development, tissues undergo precise and controlled changes in shape and size. Various 
signaling pathways regulate these changes, temporally and spatially, by altering cytoskeleton 
dynamics to alter cell shape. One such pathway involves the Shroom and Rock proteins that 
reorganize the actomyosin cytoskeleton in epithelial cells to alter tissue morphology. The 
Shroom family of proteins are multi-domain, actin-binding proteins required for many 
developmental processes such as neural tube formation, and retinal morphogenesis.  Shroom 
proteins interact with Rho-kinase (Rock), another conserved cytoskeleton regulator, to activate 
non-muscle Myosin II and assemble a contractile actomyosin network.  All Shroom proteins 
contain a highly conserved C-terminal domain called Shroom Domain 2 (SD2) that interacts with 
the Rock Shroom binding domain (SBD) and is required for Shroom-mediated apical 
constriction. In the Shroom-Rock system it is unclear how this interaction activates the kinase 
activity of Rock. The goal of this dissertation is to understand the mechanistic details of the 
Shroom-Rock interaction. Using structural studies I have started to dissect the SD2-SBD 
interaction. I first determined the crystal structure of the Drosophila Shroom SD2 domain at 2.7 
Å resolution to be a novel fold composed of a three-segmented, anti-parallel, coiled-coil dimer. 
Using mutational analysis and a combination of in vivo and in vitro assays we identified surfaces 
within the central coiled-coil segment of the SD2 domain that mediate Rock binding. The anti-
parallel nature of the SD2 domain introduces internal symmetry into the SD2 domain such that 
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there are two identical binding sites for Rock on opposite sides of the molecules suggesting 
interesting implications for the Shroom-Rock interaction. We also determined the crystal 
structure of the Rock SBD to 2.5 Å resolution and saw that it is a parallel coiled-coil dimer. 
Using mutational analysis combined with biochemical assays I have identified two conserved 
patches on opposite ends of Rock SBD that are required for Shroom interaction. These patches, 
unlike the patches on the SD2 domain, are not identical. Biochemical characterization of the 
SD2-SBD complex suggests that molar ratio of this complex is 1:1. Based on these results we 
can start to suggest models for how Shroom and Rock interact. 
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1.0  INTRODUCTION 
During development tissues undergo controlled changes in shape and structure culminating in a 
highly organized embryo. In most animals, common types of morphogenetic events such as 
tissue folding or tissue elongation bring about changes in embryonic tissue. Bending of epithelial 
sheets is a central morphogenetic process that is required for the formation of the gut, the eye, 
and the neural tube (Fig. 1). This bending is facilitated by a combination of apical constriction 
and cortical tension along the apicobasal axis. Further, at the cellular level intrinsic and extrinsic 
elements, such as the extracellular matrix and the cytoskeleton, provide the forces required to 
alter cell shape to drive bending of epithelial sheets. The forces that shape epithelial tissues are 
regulated spatially and temporally by a variety of proteins that regulate the cytoskeletal 
dynamics. Forces generated locally on a single cell need to be coordinated throughout the 
epithelial sheet for proper bending to occur. The cytoskeleton also plays a role in integrating 
these local signals and forces to produce coordinated movements in sheets of epithelial cells. 
Thus, tight regulation of the cytoskeleton is key to proper embryonic development. 
The major cytoskeletal proteins that alter epithelial cell shape are myosin II and actin 
filaments. Myosin II binds actin filaments to generate the force required for epithelial 
morphogenesis. Together these proteins form the basic molecular force that drives tissue 
morphogenesis, and not surprisingly require precise regulation of their subcellular localization 
and activation. In epithelial cells, the activity of myosin II is primarily regulated by Rho-kinase. 
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Rho-kinase phosphorylates and activates the actin associated ATPase activity of myosin II [1]. 
Epithelial cells can regulate the activity of the actin-myosin (actomyosin) network by regulating 
the subcellular localization of Rho-kinase. In a number of epithelial cells, the actin binding 
protein Shroom interacts with Rho-kinase (Rock) and recruits it to apical surfaces [2]. Apart 
from altering Rock subcellular localization Shroom proteins also reorganize and alter the 
subcellular localization of actin filaments [3, 4]. Via the Shroom-Rock interaction non-muscle 
myosin II is activated at apical surfaces resulting in the formation of a contractile actomyosin 
cytoskeleton. This reorganization of the actomysoin cytoskeleton by the Shroom and Rock 
proteins is required for various developmental processes such as neural tube closure, retinal 
morphogenesis, and the development of vasculature [3, 5-7]. There are several aspects of the 
Shroom-Rock pathway that are still unclear. The biggest unanswered question in this pathway is 
how Rock is activated upon binding Shroom. This dissertation will focus on understanding the 
Shroom-Rock interaction to gain insight into the regulation of actomyosin dynamics during 
embryonic development. 
1.1 EPITHELIAL MORPHOGENESIS 
Epithelial cells undergo highly coordinated cell shape changes during embryogenesis. There are 
several general morphogenetic processes such as, intercalation, invagination, sheet extension, 
and tube formation, elongation and constriction that bring about changes in epithelial sheets. At 
the cellular level a mixture of apical constriction and asymmetric cortical tension drives these 
processes. Myosin II is the primary cytoskeletal motor that drives shape change in epithelial 
cells. In epithelial cells, activated myosin II walking along actin filaments generates the 
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contractile force required to shrink the apical surfaces (reviewed in [8]). Understanding the 
regulation of epithelial morphogenesis will provide insight into how organisms orchestrate 
complex changes in tissue architecture during development. 
 
 
 
 
 
Figure 1: Common tissue morphogenetic events. 
(A) Invagination is a process during which a few cells apically constrict to facilitate the inward folding of a sheet 
of cells. 
(B) During tube formation epithelial cells apically constrict and elongate to convert a sheet of cells into a tube. 
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 1.1.1 Apical Constriction 
Apical constriction is a process where the actomyosin network, localized to the apical surface of 
cells, contracts resulting in shrinking of cellular apices. During development, apical constriction 
is important for various morphogenetic processes such as tissue bending, tube formation, 
invagination, and internalization of small numbers of cells. In many organisms apical 
constriction commonly occurs during gastrulation when the three germ layers are established. In 
X. laevis and sea urchins apical constriction drives the primary invagination of cells during the 
formation of the archenteron or the primitive gut [9-11]. Apical constriction also drives the 
ingression of cells during gastrulaion in C. elegans [12]. In fruit files apical constriction regulates 
ventral furrow formation, internalization of the mesoderm, dorsal closure, eye development, and 
the formation of the salivary glands and tracheal tubes [13-17]. Apical constriction also plays a 
role in shaping tissue during neurulation in vertebrates [18]. During development of the central 
nervous system, a flat epithelial sheet called the neural plate bends, extends, and folds into the 
neural tube. Neural tube closure is driven by apical constriction of cells in the neural plate [19, 
20]. Thus, apical constriction is a conserved process used by most animals to bring about 
changes in tissue shape during embryogenesis. 
Numerous signaling pathways regulate apical constriction by controlling the actomyosin 
cytoskeleton dynamics. In several of these processes, Rho GTPases and Rho-kinase activate 
myosin II and trigger the formation of a contractile actomyosin network [2, 4, 21-28]. During 
neural tube closure circular bands of actin filaments accumulate at the apical junction and non-
muscle myosin II binds to these actin filaments [29]. The actin binding protein Shroom3 is one 
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of the most important cytoskeletal regulators required for neural tube closure [2, 3, 30]. Shroom3 
recruits the actin binding proteins Ena/VASP and cell adhesion proteins nectin-2 and N-cadherin 
to the apical side of neuroepithelial cells [5, 31-35]. Shroom3 also binds to Rho-kinase and 
recruits it to the apical side of neuroepithelial cells where it phosphorylates and activates non-
muscle myosin II [2, 4]. Accumulation of F-actin and activated myosin at the apical surfaces of 
cells always precedes apical constriction [9]. While the upstream regulators of all these 
developmental processes vary greatly the central effectors that cause apical constriction and alter 
cell morphology are actin filaments and myosin II motors. 
1.1.2 Actomyosin Cytoskeleton 
Myosin II and actin filaments are the major cytoskeletal proteins that bring about changes 
cell shape. Non-muscle myosin II is an actin-based motor that is composed of two heavy chains, 
two essential light chains and two regulatory light chains. Each heavy chain is composed of an 
N-terminal globular head domain that has the actin-binding and ATP-binding sites. Following 
the head domain is an alpha helical neck region that is thought to act as a lever arm [36]. The C-
terminal portion mediates dimerization and filament formation. The light chains are small 
proteins interact with the neck and head regions of the heavy chains. Myosin motors attach and 
detach from actin filaments in a cyclical manner. When bound to ATP, myosin II can bind to 
actin filaments. Upon binding actin filaments myosin undergoes a conformational change that is 
coupled to ATP hydrolysis. This ATP hydrolysis moves the myosin motor along the filament 
resulting in displacement of the filament [37]. This myosin II stroke activity can reduce the 
overall length of junctional membrane between cells and accumulation of myosin II at apical 
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surfaces can cause the apical plasma membrane to shrink. The contractile forces generated by 
myosin II motors walking along actin filaments drive epithelial cell shape change. 
Tissue morphogenesis requires a balance between stiffness and contractility, both of 
which depend on the actomyosin network [38]. Actomyosin contractility in epithelial cells 
undergoing morphogenesis is not completely understood. Epithelial cells undergoing apical 
constriction contain activated myosin II that colocalizes and binds to circular bands of actin 
filaments accumulated at apical surfaces. Contracting epithelial cells display dynamic 
actomyosin activity where actin and myosin transiently accumulate at the cell cortex and 
condense to form foci. This accumulation of condensed actomyosin foci is correlated with pulses 
of cell contraction [39, 40]. These pulses of cellular contraction need to be stabilized for 
productive tissue contraction. Models describing changes in tissue shape suggest that the 
junctional actomyosin network acts as a ratchet that maintains the contraction generated by the 
medial network. Alternatively, high frequency of foci formation can result in rapid contraction 
and surpass the need of the junctional ratchet [39]. Here, transition to a supracellular actomyosin 
network stabilizes the fluctuations in cellular contractility and increases tissue stiffness [41, 42]. 
Actomyosin dynamics is required for various aspects of tissue morphogenesis during 
development. 
The spatial and temporal regulation of actomyosin activity is key to coordinating the 
morphogenetic events that control epithelial morphogenesis. Myosin II motor activity is 
regulated by phophosrylation of the regulatory myosin light chain, which increases the ATPase 
activity of myosin II allowing it move along actin filaments [43]. In epithelial cells, Rock is the 
primary kinase that phosphorylates the regulatory myosin light chain and activates non-muscle 
myosin II [1]. The regulation of actomyosin dynamics can be controlled by spatially and 
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temporally regulating the activation of Rock. Thus, understanding the mechanisms that activate 
Rock provide insight into how cytoskeleton dynamics is regulated to bring about changes in cell 
shape during development. 
1.2 RHO-KINASE 
Rock is a major cytoskeleton regulator that causes cytoskeletal rearrangements by activating 
myosin II. It is important for various processes such as smooth muscle contraction, formation of 
stress fibers and focal adhesion complexes, intermediate filament disassembly, neurite 
rectraction, microvilli formation, cytokinesis and cell migration [44-53]. The actin-induced 
ATPase activity of myosin II is activated upon phosphorylation of Ser-19 of the regulatory 
myosin light chain (MLC). MLC phosphatase inactivates myosin II by removing the 
phosphorylation mark at Ser-19 on MLC [54-56]. Rock directly activates myosin II by 
phosphorylating MLC at Ser-19 allowing myosin II to associate with actin. Additionally, Rock 
phosphorylates MLC phosphatase at Thr-697 and Ser-854, inhibiting the phosphatase activity of 
MLC phophatase and increasing the active population of myosin II [1, 57-60]. In addition to 
MLC and myosin phosphatase, Rock targets several other proteins that are involved in 
cytoskeleton dynamics. Rock phosphorylates Ezrin/Radixin/Moesin family of proteins that play 
a role in linking actin filaments with the plasma membrane [61-63]. Another actin binding 
protein, adducin, is phosphorylated by Rock and this mark is required for membrane ruffling and 
cell motility [53, 64]. Rock also plays a role in stabilizing actin filaments by phosphorylating 
LIM-kinases [65]. This phosphorylation mark enhances the kinase activity of LIM-kinases to 
phosphorylate and inactivate the actin-depolymerizing protein cofilin [66]. Lastly, Rock also 
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phosphorylates and induces depolymerization of intermediate filaments during cytokinesis [45, 
50, 67]. Thus, Rock is a central cytoskeleton regulator that plays a key role in controlling 
cytoskeleton dynamics. 
Rho-kinase (Rock) is a Ser/Thr protein kinase identified in various biochemical assays 
performed to find binding partners for the GTPase Rho [68-70]. There are two Rock isoforms, 
Rock I and Rock II, that share 64% overall identity [47, 70-72]. Rock I and Rock II are both 
expressed in most tissues; however, there are a few differences in the expression pattern of the 
two isoforms and in their roles in regulating cytoskeleton dynamics [71, 72]. Both Rock I and II 
have a N-terminal kinase domain, a central region predicted to have an alpha helical coiled coil 
motif and a Rho binding domain located at the end of this coiled coil region (Fig. 1A) [47, 69, 
73]. The very C-terminal portion of Rock contains a pleckstrin homology domain split by a 
cysteine rich region (Fig. 1A) [69, 70]. Both Rock isoforms bind GTP-RhoA and have the highly 
conserved N-terminal kinase domain that shares 44% sequence identity to myotonic dystrophy 
kinase [68, 69, 71].  
1.2.1 The kinase domain of Rock 
The Rock kinase domain is the most conserved region of the protein and is 95% identical in 
Rock I and Rock II [47, 72]. The crystal structure of the kinase domain from Rock I reveals that 
this domain has a typical Ser/Thr kinase fold consisting of two lobes linked by a hinge [74]. The 
structure also revealed that the kinase domains dimerize in a head to head manner using an N-
terminal α-helical dimerization domain and the kinase tail [74]. The dimer interactions orient the 
two monomers such that active sites of the kinase domains appear on a single face.  This was the 
first structure of a kinase domain from the mytonic dystrophy kinase family. Structural 
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alignments with other kinase domains revealed that the PKA kinase domain and Rock kinase 
domain align with a root mean square deviation of 1.3 Å [74]. Structural comparisons revealed 
that the Rock kinase domain resembled the catalytically active conformation of the PKA kinase 
domain. The residues in the Rock kinase active site arranged in a manner similar to the residues 
in the active site of the activated PKA kinase domain and the Rock activation loop resembles an 
active conformation [74, 75]. In many kinases the catalytically competent conformation is 
stabilized by phosphorylation of a serine or threonine on the activation loop. No such 
phosphorylation mark was seen in the crystal structure of the Rock kinase domain suggesting 
that phosphorylation of the activation loop might not be essential for Rock activation [74]. These 
results indicate that the Rock has a canonical Ser/Thr kinase domain that is activated in a 
phosphorylation independent manner. 
1.2.2 Regulation of Rock activity 
Similar to myotonic dystrophy kinase Rock proteins have an autoinhibitory C-terminal 
region [76, 77]. The C-terminal region, consisting of the Shroom-binding domain, Rho-binding 
domain, and the split pleckstrin homology (PH) domain, can interact with the N-terminal kinase 
domain and inhibit the kinase activity of Rock [76, 78].  Additionally, deleting the C-terminal 
region results in constitutively active Rock [47, 48]. Autoinhibtion of Rock can be relieved by 
numerous mechanisms the most common of which is by association with activated GTP-Rho [1, 
57, 68-70]. Rock acts downstream of Rho in numerous processes including the formation of 
stress fibers and focal adhesions, smooth muscle contraction, and several others [46, 48, 49]. 
Interaction with activated GTP-RhoA can recruit Rock to the plasma membrane and is thought to 
relieve the autoinhibition of the N-terminal kinase domain of Rock [70]. Other activation 
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mechanisms include binding to lipids, cleavage of the C-terminus of Rock by Caspase-3 or 
oligomerization [78-81]. These observations suggest that Rock kinase activity is dependent on 
the Rock C-terminal region and the effector proteins that interact with this region.  
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 Figure 2: Domain profile and Activation Schematic of Rock. 
(A) Domain architecture of Rock. The kinase domain is shown in green and the binding regions for Rock binding 
partners are shown in blue. The conservation of each domain shown as black bars underneath. The conservation 
was obtained from a multiple sequence alignment of 16 Rock I and Rock II proteins in ClustalW. The image 
was created in JalView. 
(B) Regulation of the kinase domain by the C-terminal region of Rock and Rock effectors. The autoinhibition by the 
C-terminal region of Rock relieved by interaction with Rhoa or lipids. 
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1.2.3 Rho-binding domain of Rock 
The Rho binding domain of Rock belongs to the class II group of Rho binding motifs that 
includes mostly coiled coil proteins [73, 82]. This domain in Rock corresponds to approximately 
80 amino acids at the end of the central coiled coil region (934-1015 in human Rock). There are 
two patches within these 80 amino acids that are required for Rho binding, 934-945 and 1005-
1015 [73]. The structures of the Rho binding domains (RBD) from Rock I and Rock II have been 
determined to be parallel coiled coil dimers [83, 84].  The structure of Rock I RBD was solved in 
complex with GTP-RhoA while the structure of Rock II RBD was solved in its unbound form. 
Structural comparison of both the RBDs indicates that while there are differences in the N-
terminal and central portions of the coiled coil RBD dimer, the C-terminal portions are very 
similar [84]. Mutational analysis identified residues that are important for the Rho-Rock 
interaction and these residues localize to the C-terminal portion of the RBD crystal structures 
[47, 73, 83, 84]. The structure of the Rock-RhoA complex revealed that both the helices in the 
coiled coil interact with the switch regions of RhoA. The Rock-RhoA interaction is primarily 
mediated by hydrophobic interactions with a few electrostatic interactions at the edges of the 
binding interface [84]. The hydrophobic interactions at the RhoA-Rock interface resemble the 
hydrophobic interactions at the Cdc42-PAK1 interface [85]. Cdc42 activates autoinhibited PAK1 
kinase domain by causing a conformational change upon binding to the kinase [85, 86]. Since 
RhoA and Rock interact in a manner similar to Cdc42 and PAK1 it is possible that GTP-RhoA 
could cause a conformational change upon binding to the Rock RBD resulting in dissociating the 
C-terminal region from the kinase domain (Fig. 1B). The structures of the Rock RBDs revealed 
that RhoA interacts with a small patch of residues in the RBD of Rock and via this interaction 
RhoA could induce a conformational change that activates the kinase activity of Rock. 
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1.2.4 PH domain of Rock 
Rock can also be activated by binding to lipids such as arachidonic acid or PI(3,4,5,)P3 using its 
PH domain [72, 87]. The structure of the split PH domain from Rock II has been determined 
using NMR [88]. This domain in Rock has a canonical PH fold consisting of 7 β‐strands and a 
C‐terminal  α‐helix.    In Rock  the  PH domain  is  split  between β6 and β7 by a cysteine rich 
region that folds into a C1 domain [88]. C1 domains from other proteins have been known to 
bind phorbol esters and DAG. The Rock C1 domain, however, lacks the phorbol ester/DAG 
binding motif and most likely does not interact with these molecules. Additionally, the Rock II 
spilt PH domain lacks the canonical phosphoinsositol lipid binding motif instead, it has a flat 
positively charged surface at the C-terminal end that mediates interactions with lipid membranes 
with PI(3,4,5)P3, PI(3,4)P2 or PI(4,5)P2 embedded in them [88]. It is possible that via its 
interactions with the lipids Rock could be activated and recruited to the plasma membrane.  
1.2.5 Shroom-binding domain of Rock 
During development, Rock can activate non-muscle myosin II and induce apical constriction 
causing epithelial cells to invaginate. During mesoderm invagination in fruit flies RhoGEF2 is 
activated and anchored to the plasma membrane [22, 25].  This in turn results in activation of 
Rho1 and Rock resulting in apical constriction. Rock is also required for Shroom mediated apical 
constriction especially during neural tube closure in vertebrates and dorsal closure in fruit flies 
[2, 4, 89]. In epithelial cell lines as well as neuroepithelial cells Shroom proteins recruit Rock to 
the apical junctions or apical surfaces. In these cells phosphorylated MLC also colocalizes with 
Shroom and Rock at the apical junctions [2]. In Shroom the highly conserved C-terminal SD2 
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domain mediates this interaction and both Rock I and Rock II bind equally well to the Shroom 
SD2 domain [2]. Via this interaction, Shroom recruits Rock to the apical junction during 
development to activate non-muscle myosin II and induce apical constriction. 
The Shroom-Rock interaction was identified in a pull-down assay screening for 
molecules that interact with the Shroom SD2 domain [2]. The Shroom binding domain in Rock is 
located in the central coiled coil region and is distinct from the Rho binding domain (Fig. 1A) [2] 
[unpublished data from VanDemark and Hildebrand labs]. Activation of Rock in the Shroom-
Rock pathway occurs independent of Rho or lipids. RhoA and Shroom bind Rock independently 
and RhoA is not required for Shroom mediated apical constriction [5, 90]. Activation of Rock 
during Shroom mediated apical constriction most likely occurs via a unique mechanism different 
from the ones described above. Understanding the Shroom-Rock interaction will allow us to 
further understand Rock activation and its role in cytoskeleton dynamics. 
1.3 SHROOM FAMILY OF PROTEINS 
Shroom proteins are conserved actin binding cytoskeleton regulators that play an important role 
in a wide variety of developmental processes. There are four Shroom family members, Shroom 
1-4, and they are mainly expressed in epithelial cells [91]. Most Shroom proteins have an N-
terminal PDZ domain and two conserved domains only found within the Shroom family of 
proteins.  These two domains are called Shroom Domain 1 (SD1) for the centrally located 
domain and Shroom Domain 2 (SD2) for the C-terminally located domain [3] (Fig. 2). The C-
terminal SD2 domain is the most conserved domain, is found in all Shroom proteins and is 
essential for Shroom function [3, 92, 93]. Shroom3 is the best-characterized member of this 
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family of proteins. It has been shown to bind to F-actin and mediate epithelial morphogenesis by 
inducing apical constriction. The other members of the Shroom family also have roles in 
regulating cell morphogenensis; however, they differ from Shroom3 in their actin binding 
properties and subcellular localization [93]. Shroom proteins from invertebrates and Shroom2 
bind to cortical actin while Shroom4 binds to punctate actin fibers in the cytoplasm [93, 94]. All 
Shroom proteins can reorganize the actomyosin network via a conserved interaction with the 
cytoskeleton regulator Rock [2, 89]. 
However, expression of Shroom2, Shroom4 or Drosophila Shroom (dShroom) in MDCK cells 
does not cause apical constriction [93]. Therefore, while there are various conserved aspects in 
the function of the different Shroom proteins, specifically with regards to the SD2 domain, they 
play distinct roles in cellular morphogenesis. 
1.3.1 Shroom3 
Shroom3 was identified in a gene trap assay in mice where mutations in the gene resulted in 
severe neural tube defects [3]. Mice embryos with mutations in this gene have defects in neural 
tube closure that result in exencephaly, acrania and facial clefting [3]. Inhibiting Shroom3 
activity in Xenopus embryos using a dominant negative construct or a morpholino also causes 
neural tube defects [30]. In these mutant embryos the anterior folds fail to move towards midline 
thus inhibiting neural tube closure. In both mice and frog embryos Shroom3 mutations caused 
prominent anterior neural tube defects [3, 30]. During neural tube formation apical constriction is 
most pronounced at the hingepoint regions in the neural plate which form distinct lines of 
bending and facilitate movement of the neural folds [20]. Knock out analysis of Shroom3 in 
Xenopus revealed that inhibiting Shroom3 activity inhibits the formations of hingepoints which 
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in turn prevents normal bending of the neural epithelium [30]. These defects caused by Shroom3 
mutations are not due to alterations in tissue patterning, cell proliferation or cell survival [3]. 
These observations indicate that Shroom3 is required for proper neural tube formation in 
vertebrates. 
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 Figure 3: Domain architecture of Shroom proteins. 
Domain architecture of all four Shroom family members. The PDZ domain is shown in blue, the SD1 and acting 
binding regions are shown green and the highly conserved SD2 domain is shown in orange. The conservation of 
each domain is shown below as black bars. The conservation was obtained from a multiple sequence alignment of 
12 Shroom proteins in ClustalW. The image was created in JalView. 
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Shroom3 is expressed in the neuroepithelium, heart, skeletal muscle, and gut and 
localizes primarily with F-actin at apical junctions [3]. It has been shown to co-localize with F-
actin and adherens junction proteins at apical surfaces of neuroepithelium in ring like structures 
[3, 4]. Ectopically expressed Shroom3 in epithelial cells or in Xenopus blastula is also 
concentrated at the apical surface [30]. When ectopically expressed in MDCK cells Shroom3 is 
restricted to the apical junctional complex (AJC) and causes cells to undergo apical constriction 
[4]. However, not all of the cells expressing Shroom3 in a monolayer go through apical 
constriction. Cells neighboring constricted cells have expanded apical surfaces and altered tight 
junction architecture. In these cells the tight junctions appear straight and rigid instead of wavy 
as if under tension [4]. These cells most likely expand their apical surfaces to keep the 
monolayer intact. In mixed population of cells, the Shroom3 expressing cells apically constrict 
and take on a wedge shape [4]. These cells arrange themselves into tightly packed clusters at the 
apical surfaces similar to the way cells arrange themselves in the ommatidia of the Drosophila 
eye [95]. Cells in the Xenopus blastula that express exogenous Shroom3 also apically constrict 
and take on a wedge shape. This phenomenon only occurs in cells that have already established 
apical and basal polarity [30]. Shroom3 not only binds to actin filaments but also regulates the 
subcellular localization of F-actin [3, 4, 30]. In the Xenopus blastula ectopically expressing 
Shroom3, actin filaments are accumulated at the apical surfaces [30]. In cells undergoing apical 
constriction the actin fibers appear to be more condensed at the apical surface and closely 
associated with the adherens junction marker ZO-1. In the neighboring cells with expanded 
apical surfaces the stress fibers traverse the apical surfaces perpendicular to the apical-basal axis 
[4]. These experiments revealed that Shroom3 alters cell morphology by reorganizing the actin 
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cytoskeleton at apical surfaces to trigger apical constriction; however, it does not alter cellular 
polarity [4].  
The Shroom SD1 and SD2 domains are required in cis for Shroom induced apical 
constriction [30, 93]. The Shroom3 SD1 domain mediates the interaction with F-actin and 
determines the subcellular localization of Shroom and the SD2 domain triggers apical 
constriction. The SD2 domain expressed by itself in MDCK cells remains diffuse in the 
cytoplasm and dose not cause apical constriction.  However, tagging the SD2 domain with 
Endolyn and targeting it to the apical plasma membrane causes apical constriction in cells [4]. 
Alternatively, expressing a truncated form of Endolyn tagged Shroom that lacks the SD2 domain 
does not induce apical constriction. Cortical actin in cells ectopically expressing Shroom3 or 
Endolyn-SD2 is reorganized into stress fibers [4]. These results suggest that as along as the SD2 
domain is targeted to the apical membrane it is sufficient to induce apical constriction [4]. 
In addition to F-actin reorganization, Shroom3 mediated apical constriction also requires 
non-muscle myosin II and Rho-kinase (Rock) activity at the apical junctions [4]. The Shroom 
SD2 domain mediates this interaction with Rock and recruits Rock to apical junctions [2, 4]. 
Rap1 GTPase activity has also been shown to be required for Shroom3 mediated apical 
constriction [30]. Ectopic expression of Shroom3 or Endolyn-SD2 causes redistribution of 
activated non-muscle myosin II to the apical junctional complexes [4]. This Shroom3 dependent 
recruitment of F-actin and myosin II to the apical junctional complexes is also seen in 
developing embryos [4]. In neural tubes of embryos with mutations in Shroom3, F-actin is 
poorly localized to the apical surface [3]. The recruitment of actin filaments and activated 
myosin II to the apical surfaces facilitates the formation of a contractile actomyosin network that 
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can cause changes in cell shape. These results indicate that Shroom3 regulates apical constriction 
via reorganizing and redistributing the actomyosin cytoskeleton.  
During embryogenesis apical constriction is tightly coupled to apicobasal elongation. 
Microtubules are the cytoskeletal components that mediate cell elongation during neurulation 
and their assembly is primarily regulated by γ‐tubulin  [29,  96].  Shroom3  redistributes  γ‐
tubulin  resulting  in  the assembly of parallel microtubles  that drive apicobasal elongation 
[97].  Shroom3  regulates  neuroepithelial  morphogenesis  not  just  by  triggering  apical 
constri
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ction but also by regulating apicobasal elongation. 
Apart  from  regulating  neural  tube  closure  Shroom3  mediates  changes  in  cell 
morphology  in  numerous  other  developmental  processes.  Shroom3  can  associate  with 
Plenty of SH3 (POSH) and negatively regulate axon outgrowth in primary cortical neurons 
[98].   POSH is a multi‐domain scaffold protein that has roles  in regulating changes  in cell 
shape  [99].  Shroom3  binds  to  the  third  SH  domain  in  POSH  and  knockdown  of  either 
protein  causes  in  an  increase  of myosin  II  in  primary  cortical  neurons  resulting  in  axon 
outgrowth [98]. Shroom3 is also required for proper lens development in mice [5]. In the 
lens  Shroom3  expression  is  dependent  on  Pax6  a  crucial  transcription  regulator  in  eye 
development [5, 100]. During lens development Shroom3 binds to the actin binding protein 
Vasp  via  its  EVH1  binding  domain  and  recruits  Vasp  to  the  apical  surface  [5].  This 
recruitment  is  required  for  proper  apical  constriction  in  the  lens  pit  and  proper 
development  of  the  lens.    Shroom3  mediated  apical  constriction  in  the  lens  pit  is  also 
dependent on Rock activity and myosin II [5]. In Xenopus and mice Shroom3 is required for 
proper gut morphogenesis [31, 101]. In mice Shroom3 acts in conjuction with N‐cadherin 
to regulate apical constriction during gut morphogenesis  [31]. Ptix, a major  transcription 
factor involved in gut development, drives Shroom3 expression in the developing gut [31, 
101]. Shroom3 mediated apical constriction is required throughout embryogenesis for the 
development of various organs. 
1.3.2 Shroom2 
Shroom2 is also expressed primarily in epithelial cells and is implicated in regulating cell 
morphogenesis during development of vasculature, retinal pigment epithelium, and the neural 
tube [6, 7, 91, 93]. In the vascular endothelium, Shroom2 binds to cortical actin and is localized 
at cell-cell junctions [93]. During vascular morphogenesis Rock and myosin II are required to 
induce cortical tension to inhibit membrane protrusion and cell migration [102]. Shroom2 also 
plays a role in this process as deletion of Shroom2 in vascular epithelia decreases Rock and 
myosin II activity and increases angiogenesis [7]. Pigmentation in the retinal pigment epithelium 
(RPE) is the result of apical accumulation of mature melanosomes [103-105]. Mature 
melanosomes are targeted to apical surface via microtubules and actin cytoskeleton [104]. 
Shroom2 facilitates apical pigment accumulation in a Rab27a dependent manner and is required 
for proper melanosome maturation [6]. These studies suggest that Shroom2 is a central regulator 
of RPE pigmentation in Xenopus [6]. Similar to Shroom3, Shroom2 also mediates the assembly 
of microtubules in the neural plate to induce apicobasal cell elongation [91]. The majority of the 
processes regulated by Shroom proteins require myosin II activity. Additionally, Shroom2 has 
also been shown to bind to unconventional myosin VIIa in embryonic and adult epithelia [106]. 
Both Shroom2 and Myosin VIIa localize to tight junctions in a wide variety of epithelial cells 
and possibly play a role in maintaining and strengthening tight junctions. These studies suggest 
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that Shroom2 also plays a key role in regulating shape change in various types of tissues during 
embryonic development. 
1.3.3 Shroom1 and Shroom4 
Shroom1 and Shroom4 are not as well characterized as Shroom3 or Shroom2. Shroom1 is 
exclusive to Xenopus and is found in the apical surface of epithelial cells and is associated with 
epithelial sodium channel [107, 108]. Shroom4 lacks the SD1 domain and is expressed primarily 
in mesodermal tissue [91, 94].  Similar to Shroom2 and Shroom3, Shroom4 can also regulate 
microtubule assembly by altering γ-tubulin distribution [91].  Shroom4 is expressed in most 
tissues and can interact with populations of F-actin that are distinct from stress fibers or cortical 
actin [94]. Shroom4 is associated with human X-linked mental retardation and ocular alibinism 
type 1; however, its exact developmental role is unclear [92, 109]. The roles of these Shroom 
family members in development need to be further characterized. 
1.3.4 Invertebrate Shroom proteins 
Shroom proteins were identified in several invertebrate organisms such as fruit flies, sea urchins 
and sea squirts by searching for open reading frames encoding SD2 domain [93]. Among the 
Shroom proteins identified in invertebrates Drosophila Shroom is the best-characterized protein. 
dShroom lacks the N-terminal PDZ domain but has a loosely conserved SD1 region and the 
highly conserved SD2 domain [89, 93]. There are two Shroom isoforms in Drosophila, 
dShroomA and dShroomB that differ in their subcellular distribution [89]. dShroomA, the 
longest isoform, is the most abundant isoform expressed in the developing embryo [89]. The two 
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isoforms vary at the N-terminus and use different mechanisms for localization. F-actin is 
required to localize dShroomA to the adherens junctions. dShroomA binds actin filaments using 
a region that has moderate (26%) homology to vertebrate SD1 domain [89]. The shorter 
dShroomB isoform is not found at the adherens junctions; instead, it localizes to the apical 
plasma membrane of the ectoderm. While dShroomA cannot cause apical constriction in MDCK 
cells, dShroomB localizes to the apical membrane and moderately decreases the apical area [89]. 
Overexpression of either isoform in the developing Drosophila embryo causes defects in dorsal 
closure. At the cellular level these defects seem to be due to aberrant apical constriction 
occurring in cells overexpressing dShroom [89]. In these cells there is an increase in 
accumulation of F-actin and activated myosin II at the adherens junctions. The C-terminal 
regions, which contain the SD2 domain of these two isoforms, are identical. In vitro experiments 
indicated that Drosophila Rock binds to dShroom SD2 domain and Rock is required for 
dShroom mediated cytoskeletal reorganization in vivo [89]. These results suggest that the 
Shroom-Rock pathway has been conserved over animal evolution. 
1.3.5 Conserved domains in Shroom proteins 
Not all the Shroom family members have the N-terminal PDZ domain or the centrally 
located SD1 domain (Fig. 2). However, all Shroom proteins have the C-terminal SD2 domain 
and regulate myosin II activity via this domain. The SD2 domains from all Shroom proteins can 
cause actomyosin based apical constriction if targeted to the apical surface [93]. Only expression 
of full length Shroom3 can cause apical constriction in epithelial cells. However, expression of 
chimeric Shroom proteins that have the N-terminal portion from Shroom3 and the C-terminal 
SD2 domain from Shroom2, invertebrate Shroom, or Shroom4 in MDCK cells can cause apical 
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constriction [93]. Shroom directly interacts with Rock via the SD2 domain and this interaction is 
required for the recruitment of Rock and myosin II to the apical junctions [2]. It is unclear how 
the interaction between Shroom and Rock activates the kinase activity of Rock. The most 
common mechanism by which Rock is activated is by binding GTP-Rho. Binding to Rho, 
however, is not required for Shroom mediated apical constriction. Shroom3 might cooperate with 
Rho to promote apical constriction; however, it is not dependent on Rho to induce apical 
constriction [90]. Both Shroom3 and RhoA can bind Rock simultaneously in vitro indicating that 
these two proteins do not compete to interact with Rock [5]. While the N-terminal and central 
portions of Shroom bring specificity to Shroom proteins, the basic function of all Shroom 
proteins is carried out by the SD2 domain. Understanding how the SD2 domain interacts with 
Rock and recruits it to the apical junctions is key to understanding the mechanistic details of 
Shroom function. 
1.4 DISSERTATION AIMS 
The Shroom-Rock pathway is a conserved pathway found in vertebrates and invertebrates [93]. It 
is important for numerous developmental pathways including neural tube closure, dorsal closure 
in fruit files, retinal morphogenesis and several others [3, 6, 89].  Shroom is an actin binding 
protein that can localize to actin filaments and bring about changes in cell shape by reorganizing 
the actin cytoskeleton. There are four Shroom family members that differ primarily in their actin 
binding activities and subcellular localization. Shroom proteins can have a N-terminal PDZ 
domain and a centrally located SD1 domain. These domains mediate localization and the actin 
binding activity of Shroom. All Shroom proteins identified so far have a highly conserved C-
 24 
terminal SD2 domain. This domain mediates the interaction with Rock and is required for the 
basic function of Shroom. SD2 domains from any Shroom proteins can cause apical constriction 
as long as they are localized to the apical surface [2, 93]. The SD2 domain interacts with a 
conserved centrally located Shroom binding domain (SBD) in Rock [2].  
Rock proteins are highly conserved cytoskeleton regulators that phosphorylate and 
activate myosin II. In the Shroom-Rock pathway, Rock is recruited to the apical surface by its 
interaction with Shroom where it can then activate myosin II and induce a contractile actomyosin 
network. The kinase domain of Rock is autoinhibited by its C-terminal region. There are several 
known mechanisms for how the kinase domain is activated however; none of these mechanisms 
describe Rock activation during Shroom mediated apical constriction. It is possible that Rock is 
activated upon binding to Shroom or an active form of Rock binds to Shroom.  
I used structural studies to understand the mechanistic details of the Shroom-Rock 
interaction. The SD2 domain and the SBD do not have sequence homologs outside of Shroom or 
Rock. Therefore, before making predictions about the SD2-SBD complex it is necessary to first 
determine the structures of these two domains. Using x-ray crystallography I will determine the 
structures of the SD2 and SBD domains individually. Upon determining the structures of the 
individual domains I will attempt to crystallize and determine the structure of the SD2-SBD 
complex. 
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2.0  STRUCTURE OF THE SHROOM SD2 DOMAIN 
2.1 INTRODUCTION 
Shroom proteins play important roles in inducing changes in tissue shape during development. 
Mutations in Shroom result in birth defects such as excenphaly and spina bifida [3]. The SD2 
domain is the most conserved domain in Shroom. It is found in all known Shroom family 
members and is required for Shroom function.  The Shroom SD2 mediates the interaction with 
the highly conserved cytoskeleton regulator Rock. Via this interaction Rock is recruited to the 
apical junction to phosphorylate and activate non-muscle myosin II. Upon activation myosin II 
can bind actin and form a contractile actomyosin network that generates the force required for 
apical constriction. To understand the Shroom-Rock interaction I chose to first structurally 
characterize the Shroom SD2 domain. 
In collaboration with the Hildebrand lab we designed multiple SD2 constructs from 
mouse Shroom3 (mShroom3), mouse Shroom2 (mShroom2) and Drosophila Shroom 
(dShroom). The boundaries of these constructs were chosen based on conservation and 
secondary structure predictions (Fig. 3). The stability of each construct upon purification was 
assayed by limited proteolysis. These assays indicated that the shortest constructs from each 
Shroom homolog were proteolytically stable. We termed these the core SD2 domains. The 
Hildebrand lab showed that these core SD2 domains are capable of inducing apical constriction 
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in MDCK cells. These SD2 domain constructs expressed well and were easily purified to large 
quantities. We set up crystallization trials with the core SD2 domains from mShroom3, 
mShroom2 and dShroom. While the mShroom3 and mShroom2 SD2 domains did not crystallize 
the dShroom SD2 domain formed crystals in several conditions. I was able to optimize these 
crystals and collect a high quality dataset to use for structure determination. 
Using single-wavelength anomalous dispersion I determined the crystal structure of the 
Drosophila Shroom SD2 domain spanning residues 1393-1576. The structure revealed that the 
SD2 domain has a novel fold composed of an anti-parallel, three-segmented, coiled coil dimer. 
Using biochemical and cell based assays, in collaboration with the Hildebrand lab, I have shown 
that dimerization is important for Rock interaction and Shroom function. Additionally using 
mutational analysis I have identified two binding conserved patches in the SD2 domain that 
mediates interaction with Rock. These results suggest that the SD2 domain interacts with Rock 
as a dimer using its central coiled coil segment. 
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 Figure 4: SD2 constructs. 
mShroom3, mShroom2 and dShroom SD2 constructs designed for crystallographic screens. The boundaries of the 
constructs were based on conservation and secondary structure predictions. Conservation is represented as black 
bars. The secondary structure prediction is represented as orange cylinders denoting alpha helices A-G. The SD2 
domain is predicted to be composed entirely of alpha helices. The conservation was obtained from a multiple 
sequence alignment of 12 SD2 sequences using ClaustalW and JalView. The secondary structure was predicted 
using PSIPRED [110]. 
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2.2 RESULTS 
2.2.1 Crystallizing the Drosophila Shroom SD2 domain 
The core SD2 domain from Drosophila Shroom (1393-1576) was cloned into the pET-151/D-
TOPO expression vector and transformed into BL21-CodonPlus E. coli cells.  Protein expression 
was induced using the autoinduction method and dShroom SD2 expressed to a high degree (with 
a yield of ~100mg/L of culture) [111].  The dShroom SD2 domain was easily purified using 
nickel affinity chromatography and size exclusion chromatography.  Crystal screens were set up 
with the pure homogenous dShroom SD2 (≈ 98% purity) at a concentration of 10mg/ml  in 
buffer  containing  8%  glycerol,  500mM  NaCl,  20mM  Tris  PH  8.0  and  5mM  β‐
mercaptoethanol.  Crystals formed in several conditions the most promising of which were 
in crystallization buffer containing 30% PEG‐400 and CHES pH 9.5. Crystals  in this buffer 
were small cubes and after several attempts at optimization these crystals only diffracted 
to 4 Å.    For  the purpose of  structural  studies proposed here  I  require data  from crystals 
that diffract to a resolution of 3 Å or higher. I therefore chose to pursue crystals from other 
conditions. 
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 Figure 5: Optimizing dShroom SD2 crystals. 
(A) Initial needle cluster dShroom SD2 crystals. 
(B) Optimized diffraction quality rod shaped dShroom SD2 crystals. The needle cluster crystals were transformed 
into the rod shaped crystals by changing the crystallization buffer and temperature. 
 
 
 
 
 
I next chose to optimize crystals in buffer containing 1.0M Na/K Tartrate and 0.1M MES 
pH 5.5 and 4mM DTT.  These crystals were clusters of needles when crystallized at room 
temperature (Fig. 4A).  A variety of conditions were used to optimize these needle shaped 
crystals. Changing the buffer condition to 1.3-1.4M Na/K Tartrate, 0.1M MES pH 6.0, 11% 
glycerol, 0.6-1.0M Na Thiocynate and 4mM DTT and the crystallization temperature to 4°C 
transformed the crystals from thin needles to thicker rod shaped crystals (Fig. 4B).  Before 
freezing the optimized crystals I transferred them into buffer containing 1.4M Na/K tartrate, 
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0.1M MES acid pH 6.0, 0.9M Na thiocynate, 15% glycerol and 4mM DTT. Optimization of 
these conditions resulted in significantly improved crystals that diffracted to a much higher 
resolution (2.7 Å) than the previous condition. Using these crystals I collected a diffraction 
dataset to determine the structure of the SD2 domain. 
2.2.2 Determining the structure of the dShroom SD2 domain 
When crystals are shot with an x-ray beam the x-rays will diffract off the electrons in the crystal 
in all directions. These diffracted x-rays can be measured by a detector placed in front of the 
crystals and can be visualized as a spots or reflections. To determine the structure of a molecule 
using x-ray crystallography we need to calculate the indices, the intensity, and phase angle for 
each reflection measured in a diffraction pattern. The indices and the intensities can be measured 
experimentally, however, there is no way to measure the phase angles.  Instead, there are a few 
techniques that can be used to estimate phases. One of these techniques, called single wavelength 
anomalous dispersion, uses the anomalous scattering of selenium atoms to calculate phases.  
To solve the phase problem I purified selenomethionine substituted dShroom SD2 and 
obtained crystals in conditions similar to the native protein. These crystals were cryoprotected 
and frozen in a manner similar to the native protein and used to collect anomalous diffraction 
data. The majority of the dShroom SD2 crystals I screened were not ideal for data collection 
because they displayed several defects such as a high degree of mosaicity, ice rings and poor 
diffraction. After screening a variety of crystals I was able to collect data from a few that did not 
have these defects. The anomalous and native data sets were collected using the X25 beamline at 
the National Synchrotron Light Source, Brookhaven National Laboratory. Several of the datasets 
collected were of poor quality and made model refinement difficult. Using programs in the CCP4 
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suite and in Phenix I was able to analyze the processed datasets and rule out problems such as 
merohedral twinning and pseudo-translation symmetry [112]. Ultimately I was able to collect 
anomalous and native datasets that were of reasonable quality and used them to calculate phases, 
obtain a map and build a model. 
The selenomethionine substituted crystal diffracted to 2.4 Å while the native crystal 
diffracted to 2.7 Å.  Both datasets were processed using HKL2000, a suite of programs that 
allow you analyze and process diffraction data [113]. Both the native and selenomethionine 
crystals form in space group P21212 with unit cell dimensions a = 72 Å, b = 85 Å, and c = 93 Å. 
The structure of dShroom SD2 domain was determined by single-wavelength anomalous 
dispersion.  Phases were calculated at 3.5 Å from the anomalous data using the program SHELX 
C/D/E and a preliminary model was built into the resulting electron density map, using the 
macromolecular model building program COOT [114, 115]. The structure was refined against 
the 2.7 Å native data using positional, B-factor and TLS refinement with the Phenix.refine 
program within the Phenix software suite [116]. The final R-factors for the structure are 22.78 
for R-work and 28.38 for R-free.  The asymmetric unit of the crystal contains two molecules of 
the dShroom SD2 domain. The final model contains resides 1396-1571 in molecule A and 1397-
1571 in molecule B (Fig. 5). Analysis of the structure with the structure validation program, 
Molprobity, indicates that all of the residues in both chains lie in the favored regions of the 
Ramachandran plot [117]. The average B-factor for both molecules is 75.9 Å2 (Table 1).   
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Figure 6: Structure of dShroom SD2 domain. 
Ribbon diagram of the dShroom SD2 dimer.  The two SD2 molecules are shown in white (Chain A) and gold (Chain 
B). The arm and body coiled coil segments are labeled and the symmetry point is highlighted in blue. 
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Table 1: Data collection and refinement statistics for dShroom SD2. 
Data collection and refinement statistics for dShrm SD2 
 SeMet (SAD) Native 
Data Collection   
Space Group P21212 P21212 
Cell Dimensions   
a (Å) 72.2 72.8 
b (Å) 84.9 85.6 
c (Å) 93.0 93.0 
Resolution (Å) 30.0-3.5 (3.56-
3.50) 
50.0-2.7 (2.75-2.70) 
Unique Reflections 7573 16446 
Rmerge 8.5 (8.2) 6.9 (46.3) 
I/σI 42.1 (34.1) 34.2 (3.5) 
Completeness (%) 99.3 (100) 99.9 (99.9) 
Redundancy 10.0 (10.7) 8.5 (8.1) 
Refinement   
Resolution (Å)  47.0-2.7 
Rwork / Rfree  22.78/28.38 
No. atoms   
Protein  2749 
R.m.s. deviations   
Bond lengths (Å)  0.10 
Bond angles (°)  0.600 
Average isotropic B values 
(Å2) 
 75.9 
Ramachandran 
statistics 
  
Outliers  0 
Allowed  0 
Favored  100 
Values in parentheses correspond to those in the outer resolution shell. 
Rmerge = (|(ΣI - <I>)|)/(ΣI), where <I> is the average intensity of multiple 
measurements. 
Rwork = Σhkl||Fobs(hkl)|| - Fcalc (hkl)||/Σhkl|Fobs(hkl)|. 
Rfree = crossvalidation R factor for 7.3% of the reflections against which the model 
was not refined. 
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The three segments have canonical knobs-into-holes coiled coil packing interactions (Fig. 
6B).  Due to the extended nature of the structure, the dShroom SD2 domain lacks a traditional 
hydrophobic core.  However, the coiled-coil interactions make up an extensive dimerization 
interface with a buried surface area of 4577 Å2. There are several conserved leucines and 
isoleucines at the dimerization interface that interact in a manner similar to leucine zippers (Fig. 
6B).  In contrast to the SD2 domain, leucine zippers are almost always parallel coiled-coil 
proteins thus making the structure of the SD2 domain unique. The dShroom SD2 structure 
displays symmetry and asymmetry.  There is a twist in the central coiled-coil segment such that 
the arm segments are rotated away from each other by ~ 60°  (Fig.  7A).    The  dShroom SD2 
domain also has intrinsic symmetry such that one half dimer contains all of the amino acids 
 
2.2.3 dShroom SD2 domain is an anti-parallel coiled-coil dimer 
The crystal structure reveals that the dShroom SD2 domain is a dimer and the asymmetric 
unit of the crystal contains a single dimer. Each monomer is made up of three helices, denoted A, 
B and C, with the helix B being twice the length of helices A and C. In the dimer the B helices 
wrap around each other to form the “body” coiled-coil segment and the A and C helices wrap 
around each other to form the flanking “arm” segments (Fig. 5). There are a number of 
hydrophobic residues at the junction between the arm segments and the body segment that most 
likely play an important role in holding the arm segments in the observed conformation (Fig. 
6A). I performed a structural homology search using DALI to identify structures with a fold 
similar to dShroom SD2 [118].  The structural homology search did not yield any structures that 
had similarity that extended beyond a single coiled-coil segment. Thus, dShroom SD2 domain 
has a novel fold consisting of three anti-parallel coiled-coil segments (Fig.5). 
present  in  the monomer.    The half  dimers  are  also  structurally  identical  such  that when 
aligned they have a root mean square deviation of 0.6 Å (Fig. 7B). This internal symmetry 
has interesting biological implications since there are two potential binding sites for Rock 
present  on opposite  faces  of  the molecule.  The  extensive  coiled  coil  interactions  and  the 
unique symmetry suggest that the dimerization of the SD2 domain could be important for 
function. 
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Figure 7: Structural features of the Shroom SD2 domain. 
(A) Ribbon diagram of the SD2 domain shown in gold and white with the hydrophobic residues at the junction 
between the arm segment and the body segment are shown as stick diagrams in black. The hydrophobic residues are 
labeled in the inset. 
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(B) Canonical coiled coil interactions in one of the arm segments are represented as black stick diagrams. The top 
inset shows a zoomed in view of the leucine zipper like interactions. The bottom inset shows a zoomed in view of 
knobs into holes packing interactions with a surface view of one chain and a ribbon diagram of the other. 
 
 
 
 
 
2.2.4 Dimerization of the SD2 domain is important for Shroom Function 
To determine if the dShroom SD2 domain is a dimer in solution, I treated purified SD2 with 
small amounts of the chemical crosslinker glutaraldehyde.  The crosslinked species were 
resolved on an SDS-PAGE and visualized using coomassie blue staining. The dShroom SD2 
dimerized readily within seconds of being treated with glutaraldehye and longer exposure to the 
crosslinker resulted in the formation of higher order tetrameric forms (Fig. 8A).  Since the 
crosslinking experiment is not quantitative I used gel-filtration to determine the ratio of 
monomer to dimer in solution.  The dShroom SD2 domain elutes off the gel filtration column in 
two distinct peaks (Fig. 8B).  The larger peak, which corresponds to the dimer and was used for 
crystallization, makes up about 89% of the peak area.  These results indicate the dShroom SD2 
domain is predominantly a dimer in solution. 
To determine if SD2 dimerization is important for Shroom mediated apical constriction, I 
designed two mutations that cause local disruptions in the dimerization interface. Both mutations 
targeted conserved leucine and isoleucine residues that make canonical knobs-into holes packing 
interactions.  I termed the mutations homodimerization (HD) mutations.  The first mutation, HD1 
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(1468LLSL1471 to AASA), targets residues in the body segment while the second mutation, HD2 
(1546LIADARDL1553 to AAADARDA) targets residues in the arm segments (Fig. 9A).  Both 
mutations were made using site-directed mutagenesis.  
First, I determined if these mutations altered the monomer-dimer equilibrium. I analyzed 
the gel filtration elution profiles of both HD mutants to measure the monomer to dimer ratio for 
each mutant.  Neither mutant shifted the equilibrium towards the monomer species.  Instead, 
both mutants had elution profiles very distinct from the wild-type protein.  HD1 eluted off the 
gel filtration column in a single-wide peak that did not coincide with the wild-type monomer or 
dimer peak (Fig. 9B).  For HD2, the majority of the protein eluted off the gel filtration column in 
a peak larger than the wild-type dimer peak (Fig. 9B).  I pooled the fractions corresponding to 
the major peak for HD1 and the dimer peak for HD2 for the following biochemical assays. 
Limited proteolysis experiments indicated that these mutations also severely destabilized the 
proteins (Fig. 9C). Chemical crosslinking assays showed that the ability of these mutations to 
dimerize was also diminished (Fig. 9D). Native gel electrophoresis was used to test whether 
these mutants were capable of binding Rock (Fig. 10).  These experiments were performed in 
collaboration with the Hildebrand lab. Gel shift assays show that both HD mutants were deficient 
in binding to Drosophila Rock SBD. These results indicate that even local perturbations to the 
dimerization interface severely destabilize the dShroom SD2 domain.  Additionally, the Rock-
binding site is made up of residues from both chains as disrupting the dimerization interface 
disrupts interactions with Rock SBD. 
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Figure 8: Symmetry in the dShroom SD2 domain. 
(A) Ribbon diagram of the dShroom SD2 domain with the two half dimers shown in green (half dimer A) and gray 
(half dimer B). The symmetry point is highlighted in blue. 
(B) Structural alignment of the SD2 half dimers with an r.m.s.d of 0.6 Å. The two half dimers were aligned using the 
DALI server and the r.m.s.d. was calculated over 178 Cα atoms. 
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Figure 9: dShroom SD2 domain is a dimer in solution. 
(A) Chemical crosslinking of dShroom SD2 domain.  The SD2 domain was incubated with 0.009% glutaraldehyde 
for the indicated time and the resulting species were resolved with SDS-PAGE. 
(B) Gel filtration profile of dShroom SD2 domain. Purified SD2 domain was subjected to size exclusion 
chromatography. The size exclusion trace is shown in orange. The peak areas of the dimeric (crystallized) and 
monomeric peaks are indicated. The fractions collected were analyzed by SDS-PAGE, which is indicated below the 
size exclusion trace. 
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Figure 10: Mutations in the dimerization interface disrupt the stability and the fold of the SD2 domain. 
(A) Ribbon diagram of the SD2 domain with the homodimerization (HD) mutants shown as stick diagrams in red 
(HD1) and cyan (HD2). The residues interacting the mutated residues are shown in gray or gold. 
(B) Gel filtration profiles of the wild-type and HD mutant dShroom SD2 protieins. Purified wild-type and mutant 
SD2 domains were subjected to size exclusion chromatography. The size exclusion traces are shown in orange (wt), 
red (HD1), and cyan (HD2). The fractions collected were analyzed by SDS-PAGE, which is indicated below the size 
exclusion trace. 
 43 
(C) Limited proteolysis of the HD mutants. Wild-type and mutant proteins were subjected to 13ng of the protease 
Subtilisin A for the indicated time. The reaction was stopped at the indicated time with PMSF and the digested 
fragments were visualized using SDS-PAGE. 
(D) Chemical crosslinking of the HD mutants. The wild-type and mutant proteins were incubated with 0.002% 
glutaraldehyde for the indicated time. The reaction was stopped with 1M Tris pH 8.0 and the resulting species were 
resolved with SDS-PAGE. 
 
 
 
 
 
 
 
Figure 11: Mutations in the dimerization interface disrupt Rock binding. 
Native gel electrophoresis of dRock SBD (724-938) with increasing concentrations of wild-type or HD mutant 
dShroom SD2 domains. dRock SBD was mixed with wild-type or SD2 domains and incubated at room temperature 
before subjecting the proteins to Native PAGE. 
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2.2.5 The central SD2 coiled coil segment is important for the Shroom-Rock interaction 
I next took a mutational approach to identify surfaces in the SD2 domain that mediate interaction 
with Rock SBD. I first aligned 12 Shroom sequences using ClustalW to identify conserved 
patches [119].  Then, using the RISLER scoring matrix in the ESPRIPT program I scored and 
mapped the conserved residues on to the surface of the SD2 domain (Fig. 11A) [120, 121]. The 
SD2 domain has conserved residues throughout the sequence; however, there were three regions 
that had clusters of surface exposed conserved residues. I made three multiple substitution 
mutations, by site-directed mutagenesis, that targeted these three surface exposed conserved 
clusters (SC).  All three SC mutants (1402KMDEL1406 to AMDRA, 1470SLSERLA1476 to 
ALEEDLE, 1509LKSDIERR1516 to AASDIEDA) termed cluster 1, cluster 2 and cluster 3 have gel 
filtration elution profiles similar to the wild-type and show no increased sensitivity to proteases. 
Cluster 1 targets residues in the arm towards the N-terminus while cluster 2 and cluster 3 target 
conserved residues in the central body segment.  The ability of these mutations to interact with 
Rock was tested via pull-downs and native gel electrophoresis.  These biochemical experiments 
were performed in collaboration with the Hildebrand lab. Both the pull-down and gel shift assays 
indicated that while the cluster 1 mutant was still capable of binding Rock SBD, the cluster 2 and 
cluster 3 mutants were not (Fig. 11B and 11C).  Binding to Rock SBD was greatly diminished 
for the cluster 2 mutant and completely abolished for the cluster 3 mutant.  These results suggest 
that the Rock-binding surface in Drosophila Shroom lies in the central body segment of the SD2 
domain with the conserved residues in cluster 3 playing a more significant role in binding Rock 
than residues in cluster 2. 
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 Figure 12: Conserved surfaces in the SD2 central coiled coil segment are important for the Shroom-Rock 
interaction. 
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(A) Surface view of the dShroom SD2 structure with conservation highlighted in shades of blue. Conservation was 
obtained from a multiple sequence alignment of 12 SD2 sequences and scored using the RISLER matrix in espript 
[120, 121]. The invariant residues targeted for mutation in each cluster are shown in green. 
(B) Native gel electrophoresis of dRock (724-938) with increasing concentrations of wild-type or SC mutant 
dShroom SD2 domains. dRock SBD was mixed with wild-type or SD2 domains and incubated at room temperature 
before subjecting the proteins to Native PAGE. 
(C) Pull-down assay using his-tagged dRock (724-938) and wild-type or mutant dShroom SD2 proteins. His-tagged 
dRock bound to nickel beads was incubated with an excess of untagged wild-type or mutant SD2. The ability of the 
wild-type and mutant SD2 to bind to dRock was assayed by resolving the nickel beads and the supernatant using 
SDS-PAGE. 
 
 
 
2.2.6 The Rock binding surface is conserved in vertebrate Shroom 
To determine if these conserved residues also play an important role in Rock binding in 
vertebrates, the Hildebrand lab made the surface cluster and homodimerization mutants in the 
mouse Shroom3 SD2 (mShroom3) domain.  We assayed the ability of these mutants to bind 
Rock and induce apical constriction using biochemical and cell based assays.  GST pull downs 
showed that the cluster 1 mutant could bind Rock SBD; however, the cluster 2, cluster 3 and 
both of the homodimerization mutants cannot (Fig. 12A). Through GST pull-downs we also 
determined that the mShroom3 homodimerization mutants could not dimerize (Fig. 12C). These 
results are consistent with the results seen with the Drosophila SD2 domain; however, it looks 
like the residues in cluster 2 might play a more significant role in binding Rock in vertebrates.  
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The ability of these mutations to induce apical constriction was tested in a cell-based 
assay using MDCK cells. The surface cluster and homodimerization mutations were introduced 
into an endolyn –Shroom3 chimeric protein construct and the mutant constructs were then 
transfected into MDCK cells.  All of the mutant proteins localized to the apical junction as seen 
by co-localization with the apical junction marker ZO-1.  Consistent with in vitro binding results 
only the cluster 1 mutant was able to apically constrict cells similar to wild-type and cluster 2, 
cluster 3 and the two homodimerization mutants could not induce apical constriction (Fig. 12B).  
Based on these results we can conclude that the Rock-binding surface is located in the body 
segment of the SD2 domain and is conserved in vertebrates. 
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 Figure 13: The SD2 Rock binding interface is conserved in the vertebrates. 
(A) Pull-down assay with GST-tagged wild-type and mutant mouse Shroom3 SD2 domain and untagged hRock 
(707-946). Un-tagged hRock bound to GST beads was incubated with an of GST-tagged wild-type or mutant SD2. 
The ability of the wild-type and mutant SD2 to bind to hRock was assayed by resolving the GST beads (P) and the 
supernatant (S) using SDS-PAGE.  
(B) Endolyn tagged wild-type or mutant mouse Shroom3 was expressed in MDCK cells and stained for ZO-1 and 
Shroom3. The transfected cells are indicated by arrow heads. 
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(C) Pull-down assay with wild-type or mutant GST tagged mouse Shroom3 and untagged wild-type Shroom3. Un-
tagged mouse Shroom3 bound to GST beads was incubated with an of GST-tagged wild-type or mutant SD2. The 
ability of the wild-type and mutant SD2 to bind to untagged mouse Shroom3 was assayed by resolving the GST 
beads (P) and the supernatant using SDS-PAGE. 
 
 
 
 
 
2.2.7 Attempts to crystallize SD2 domains from vertebrate Shroom proteins 
In an effort to determine the structure of the mouse Shroom SD2 domain I designed an 
mShroom2 SD2 construct based on the Drosophila Shroom SD2 structure.  We had previously 
made several mShroom2 and mShroom3 SD2 constructs and while these proteins purified easily, 
they did not yield crystals.  The boundaries of the new mShroom2 SD2 construct were based on 
the ordered residues seen in the dShroom SD2 structure. The mShroom2 SD2 (1293-1476) was 
cloned into the expression vector pMCSG7 and transformed into BL21-CodonPlus E. coli cells. 
The protein expressed to a high degree (~200mg/L) and was easily purified (~98% purity) using 
nickel affinity chromatography, ion exchange and size exclusion chromatography. Peak fractions 
from gel filtration were dialyzed into buffer with 25mM NaCl, 20mM Tris pH 8.0, 1mM β-
mercaptoethanol and concentrated to 15mg/ml and used to set up preliminary crystal screens at 
23°C and 4°C. Thin rod shaped crystals formed in 35-39% 2-Methyl-2,4-pentanediol, 0.1 M 
Imidazole pH 8.0 and 0.2 M MgCl2 at 4°C (Fig. 13A). After several rounds of optimization the 
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crystals only diffracted to ~8.0 Å. The new mShroom2 SD2 boundaries aided in the formation of 
crystals; however, these crystals were not diffraction quality crystals. 
 
 
 
 
 
 
Figure 14: Mouse Shroom2 SD2 crystals. 
(A) Optimized wild-type mouse Shroom2 SD2 (1293-1476) crystals. (B) Optimized SER mutant mouse 
Shroom2 SD2 crystals. The SER mutation did not significantly improve the quality of mShroom2 SD2 
crystals. 
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In an effort to obtain crystals that diffract to a higher resolution I decided to use a 
technique called surface entropy reduction (SER) [122]. The SER technique attempts to improve 
crystal contact and form better quality crystals by identifying patches of large, flexible and 
charge/polar residues (K, E, Q) and mutating them to more inflexible residues (A, R).  I 
identified one such patch in mShroom2 SD2 (1410KELK1413) and mutated all three residues to 
alanine.  The SER mutant was easily purified to high degree using a scheme similar to wild-type. 
The pure and homogenous protein was dialyzed into buffer with 25mM NaCl, 20mM Tris pH 
8.0, 1mM β-mercaptoethanol and concentrated to ~23mg/ml and used to set up crystal screens.  
The SER mutant only crystallized in one condition, 3.4M Hexanediol, 0.2M MgCl2, and 0.1M 
Tris pH 8.5 at 4°C (Fig. 13B).  After several rounds of optimization these SER mutant crystals 
did not diffract past 6.0 Å. The SER mutation did not significantly improve the diffraction of 
mShroom2 SD2 crystals. 
I cloned the human Shroom2 SD2 domain (1427-1610) into the pET-151/D-TOPO 
expression vector and transformed into BL21-CodonPlus E. coli cells. hShroom2 SD2 was 
purified using nickel affinity chromatography followed by size exclusion chromatography.  The 
pure, homogenous protein was concentrated and used to set up crystal trays. Small brick shaped 
crystals formed in buffer containing 20% PEG-8000, 0.2M MgCl2, and 0.1M Tris pH 8.5.  After 
the initial rounds of refinement these crystals diffracted to ~ 8Å. Upon further optimization these 
crystals should diffract to a higher resolution, and we should be able to determine the structure of 
hShroom SD2 via a technique called molecular replacement with the dShroom SD2 model. 
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2.3 CONCLUSIONS 
Using x-ray crystallography I determined the structure of the Drosophila Shroom SD2 domain 
spanning residues 1393-1576. The crystal structure revealed that the SD2 domain is an anti-
parallel dimer with a novel fold consisting of three coiled-coil segments. The SD2 domain is 
composed of two short arm segments that flank a larger central coiled-coil segment. Using 
biochemical assays I determined that dimerization of the SD2 domain is important for interaction 
with Rock SBD. Upon mapping conserved residues on to the surface of the structure I identified 
three loosely grouped patches of highly conserved residues.  Two out of the three patches were 
located on the central coiled-coil segment while the third was located at the tip of the N-terminal 
arm. Using mutational analysis combined with biochemical and cell-based assays I determined, 
collaboration with the Hildebrand lab, that the conserved residues in the central coiled-coil 
segment are required for interaction with Rock and Shroom mediated apical constriction. The 
role of these residues is conserved in invertebrates and vertebrates. These results suggest that the 
SD2 domain interacts with Rock using conserved residues in the central coiled-coil segment. 
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3.0  STRUCTURE OF THE ROCK SHROOM BINDING DOMAIN 
3.1 INTRODUCTION 
Rock proteins are highly conserved Ser/Thr kinases that regulate cytoskeleton dynamics mainly 
by phosphorylating and activating myosin II [1]. They are involved in regulating various cellular 
processes including changes in cell shape, cell motility, and cytokinesis. Rock was initially 
identified as a Rho binding protein that acts downstream of Rho [48, 69]. Since then several 
other binding partners for Rock have been identified including the actin binding protein Shroom. 
Rock is required for most of Shroom mediated processes specifically for Shroom induced apical 
constriction [2, 89]. Rock binds the Shroom SD2 domain using a conserved, centrally located 
Shroom-binding domain (SBD). This domain is located in middle of the central coiled coil 
region and is independent of the Rho binding domain of Rock [2]. The Shroom-Rock interaction 
recruits Rock to the apical junction where it activates non-muscle myosin II and facilitates the 
formation of a contractile actomyosin network. Mutations in the SD2 domain that abolish Rock 
binding show a decrease in phosphorylated myosin II at apical junctions [123]. Rock activity is 
required for Shroom mediated apical constriction; however, it is still unclear how Rock is 
activated once it is recruited to the apical junctions. 
The kinase domain of Rock is autoinhibited by the C-terminal region [76]. This inhibition 
can be relieved when rock binds to RhoA or arachodonic acid. Rock activation in the Shroom-
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Rock pathway, however, occurs independent of Rho and is most likely a unique mechanism. 
Understanding how the SBD interacts with the SD2 domain will allow us to gain insight into 
how Rock is activated in during Shroom mediate apical constriction. For this purpose I chose to 
start by structurally characterizing the two domains individually. After determining the structure 
of the Shroom SD2 domain the next step was to determine the structure of the Rock SBD. 
The VanDemark and the Hildebrand labs designed a series of SBD constructs from 
human and Drosophila Rock based on secondary structure predictions and conservation (Fig. 
14). Based on results from limited proteolysis experiments we identified a stable core SBD 
construct that still interacts with Shroom SD2. The core SBD from hRock1 (834-913) and dRock 
(821-938) were used to set up crystallization trays. The dRock SBD did not form crystals but 
hRock SBD formed thin plate like crystals that were difficult to optimize. With the aid of a 
surface entropy reduction mutation I was able to obtain diffraction quality crystals and determine 
the crystal structure of hRock SBD using single wavelength anomalous dispersion. The structure 
revealed that Rock SBD is a parallel, coiled coil dimer with canonical knobs into holes packing 
interactions. There is a high degree of sequence conservation at the N-terminus of the structure 
and mutating residues in this conserved surface disrupts the Shroom-Rock interaction. There are 
conserved residues in the C-terminal portion that when mutated cause a moderate decrease in 
Shroom binding. 
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 Figure 15: Rock SBD constructs. 
SBD constructs from hRock1 and dRock designed for crystallographic screens. The boundaries of these constructs 
were determined based on conservation (indicated as black bars) and disorder predictions. The conservation was 
obtained by a multiple sequence alignment of 16 SBD sequences in ClustalW. The disorder profile was calculated 
using DISOPRED [119, 124]. 
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3.2 RESULTS 
3.2.1 Crystallizing the Human Rock SBD 
The core hRock SBD (834-913) was cloned into the expression vector pET-151/D-TOPO 
expression vector and transformed into BL21-CodonPlus E. coli cells.  Protein expression was 
induced via autoinduction and the protein yield was modest (15mg/L) [111]. hRock SBD was 
purified to ~99% purity using nickel affinity, ion exchange and size exclusion chromatography. 
Peak fractions from the size exclusion column were pooled, concentrated to 15mg/ml in buffer 
containing 8% glycerol, 500mM NaCl, 20mM Tris pH 8.0 and 1mM β-mercaptoethanol and 
used to set up crystallization screens.  hRock SBD crystallized in a few conditions, however, 
even after several rounds of optimization these crystals only diffracted to ~8.0 Å. The initial 
crystallization attempts did not yield diffraction quality crystals so altering buffer conditions 
might improve crystal quality. 
To aid with crystallization I dialyzed the purified hRock SBD into buffer containing 2% 
glycerol, 150mM Nacl, 20mM Tris pH 8.0 and 1mM β-mercaptoethanol.  After dialysis the 
protein was once again concentrated to 15mg/ml and new crystallization screens were set up at 
4°C and room temperature. The protein crystallized in several conditions at 4°C and at room 
temperature.  The crystals at 4°C did not yield diffraction quality crystals. The conditions at 
room temperature were more promising  yielding  thin  plate  like  crystals  that  crystallized  in 
clusters (Fig. 15).   These crystals also proved to be difficult to optimize.  Apart from altering 
buffer conditions I also attempted to optimize these crystals with an additive screen and a 
technique called seeding. Seeding is used to improve crystal quality by trying to generate 
individual well-formed crystals.  Usually poor quality crystals are crushed and made into “seeds” 
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that will serve as nucleation points.  Ideally adding a dilute amount of these seeds to a drop that 
has no crystals should allow the protein to form individual better quality crystals. For hRock 
SBD I used to seeding to transform the plate clusters of crystals to thicker individual plates (Fig. 
15).  The additive screen, which involves the addition of a small amount of 96 different 
compounds to the crystallization buffer, also yielded improved crystals. Optimized crystals from 
seeding and the additive screens were transferred to a cryoprotectant buffer that contained the 
well solution plus 20% glycerol and then flash frozen.  These optimized crystals unfortunately 
only diffracted to 3.5 Å. Altering buffer conditions and seeding improved the hRock SBD 
crystals; however, these crystals did not diffract to a resolution high enough for structure 
determination. 
To  improve  the  quality  of  the  hRock  SBD  crystals  I decided to turn to a technique 
called surface entropy reduction to improve crystal contact. Surface entropy reduction involves 
identifying patches of large, flexible, charged/polar residues (E, K, Q) in the protein sequence 
and mutating one of these patches to a more inflexible residue (A, R) [122]. I identified two such 
patches in the hRock SBD sequence and mutated the least conserved patch (884EKE886?AAA) 
using site directed mutagenesis.  The plasmid encoding the SER mutant was transformed into 
BL21-CodonPlus E. coli cells and expression was induced using autoinduction.  The SER mutant 
was purified (to ~99% purity) in a manner similar to the wild-type, and the peak fractions from 
size exclusion column were pooled and dialyzed into buffer containing 150mM NaCl, 20mM 
HEPES pH 7.5 and 1mM β-mercaptoethanol.  After dialysis the SER mutant was concentrated to 
5mg/ml and used for crystallization trials.   1
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 Figure 16: Human Rock SBD crystals. 
Optimization of human Rock SBD (834-913) crystals with the use of seeding and surface entropy reduction (SER) 
mutation. The initial plate clusters crystals are shown in the first panel. The optimized SBD crystals obtained using a 
seeding and additive screens are shown in the middle panel. The high quality crystals obtained from SER mutations 
are shown in the last panel. 
 
 
 
 
 
The protein crystallized in several conditions the most promising of which were in 
crystallization buffers containing 20% PEG 3350 and 0.2 MgCl2, 2.0M ammonium sulfate and 
0.1M sodium citrate pH 5.5, and lastly buffer containing 10% PEG-8000, 0.1M imidazole pH 8.0 
and 0.2M calcium acetate.  In all of these conditions the SER mutant protein formed thick bi-
pyramidal crystals.  In addition to optimizing the buffer conditions I once again used the additive 
screen and the seeding technique to improve crystal quality.  While the additive screen did not 
improve crystal quality, the seeding technique produced diffraction quality crystals in 
crystallization buffer with 0.6-1.0M ammonium sulfate, and 0.1M sodium citrate pH 6.0 (Fig. 
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15).  To solve the phase problem I purified selenomethionine substituted protein and crystallized 
it in conditions similar the native protein. The optimized native and selenomethionine crystals 
were transferred into a cryoprotectant buffer containing 2.5M ammonium sulfate, 20% glycerol, 
150mM NaCl and 0.1M sodium citrate pH 6.0 and then flash frozen. I was able to obtain high 
diffraction quality hRock SBD crystals using SER mutations. 
3.2.2 Determining the structure of hRock SBD 
Native and anomalous data were collected using the X25 beamline at the National Synchrotron 
Light Source, Brookhaven National Laboratory.  Both the native and anomalous datasets 
diffracted to 2.5 Å and diffraction data was processed using HKL2000 [125]. These crystals 
belong to the space group C2 with unit cell dimensions a = 142.4 Å, b = 56.2 Å, c = 80.7 Å and α 
= γ = 90° and β = 119.2°. In spite of high resolution of the anomalous dataset I was only able to 
use anomalous data up to 4.0 Å to calculate phases and get an electron density map using the 
SHELX program [115]. An initial model was built using COOT into this 4.0 Å map [114]. I had 
difficulty refining the model against the anomalous or the native datasets and the R-factors were 
high (Rwork/Rfree = 44.6/47.4). Even after I corrected the geometry, position and occupancy of all 
the residues in the model, the R-factors were higher than expected for a dataset of 2.5 Å 
(Rwork/Rfree = 34.7/40.1). Additionally the electron density map lacked the detail expected for a 
dataset of this resolution. There was poor density around the side chains and aberrant positive 
difference density where the model was already built in (Fig. 16A). This indicated that there was 
a problem with the datasets and not the model.  
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 Figure 17: Ellipsoidal filtering improved electon density map quality. 
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(A) Electron density map (in blue), contoured at 1σ, of the hRock SER mutant data before ellipsoidal filtering to 
remove the poorly measured reflections. The positive difference density is shown in green and the negative 
difference density is shown in red. The model is represented as stick diagrams. There is poor electron density around 
several side chains and aberrant positive and negative electron density.  
 (B) Improved electron density map (blue), contoured at 1σ, of the hRock SER mutant after ellipsoidal filtering to 
remove the poorly measured reflections. The model is represented as stick diagrams. Ellipsoidal filtering improved 
the quality of the electron density map. 
 
 
 
Figure 18: hRock SBD data has severe diffraction anisotropy. 
F/sigma is plotted against resolution for the three directions of diffraction to determine at what resolution the 
F/sigma drops below 3 in each direction. This graph indicates that the diffraction data goes out 2.5 Å in the a* and 
the c* directions but only out to 3.1 Å in the b* direction. 
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Analysis of the processed datasets did not indicate the presence of more common 
problems such as merohedral twinning or pseudo-translational symmetry. So I decided to look at 
other crystallographic defects that could account for the issues seen with the data. Sometimes 
proteins pack more uniformly in one direction over another causing the crystal to diffract 
unequally in all directions.  This is called diffraction anisotropy and in severe cases it can result 
in an ellipsoidal diffraction pattern instead of a spherical one. Current data processing programs 
cannot account for the ellipsoidal diffraction pattern and include poorly measured reflections in 
the data, specifically in the weakly diffracting direction, thus introducing a lot of noise into the 
dataset. Coiled coil proteins have been known to display diffraction anisotropy [126]. Since 
Rock SBD is predicted to be a coiled coil protein, I analyzed the diffraction data from the Rock 
SBD SER mutant crystals for diffraction anisotropy using the Diffraction Anisotropy Server 
[127]. This analysis indicated that the native data diffracted to 2.5 Å in the ‘a’ and ‘c’ directions 
but only to 3.1 Å in the ‘b’ direction (Fig. 17). After determining the resolution cut offs for each 
direction the server performed ellipsoidal truncation to remove most of the weakly measured 
reflections from the dataset. I used the truncated native data for further refinement and building 
and saw an immediate improvement in refinement statistics (Rwork/Rfree = 30.1/32.8) and the 
electron density map (Fig. 16B). After a few more rounds of refinement and building I was able 
to improve the R-factors to Rwork/Rfree = 25.8/30.1. There are four SBD molecules in the 
asymmetric unit and current structure contains residues 836-904 in molecule C, 838-902 in 
molecule D, 837-902 in molecule E, and 838-903 in molecule F. Analysis of the structure with 
Molprobity indicates that all of the residues in both chains lie in the favored regions of the 
Ramachandran plot [128]. The average B-factor for both molecules is 47.5 Å2  (Table 2). Using 
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ellipsoidal truncation I was able to correct anisotropic diffraction in the data and determine the 
structure of the hRock SBD at 2.5 Å. 
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Table 2: Data collection and refinement statistics for hRock1 SBD 
Data collection and refinement statistics for hRock1 SBD 
 SeMet (SAD) Native 
Data Collection   
Space Group C2 C2 
Cell Dimensions   
a (Å) 141.6 142.5 
b (Å) 56.1 56.2 
c (Å) 80.4 80.7 
α = γ (°) 90 90 
β (°) 119.0 119.1 
Resolution (Å) 50.0-2.4 (2.44-
2.40) 
50.0-2.5 (2.54-2.50) 
Unique Reflections 21426 17172 
Rmerge 8.7 (65.7) 7.6 (54.7) 
I/σI 27.0 (1.6) 30.7 (1.9) 
Completeness (%) 98.9 (93.8) 88.6 (56.1) 
Redundancy 6.1 (4.1) 5.7 (4.9) 
Refinement   
Resolution (Å)  50.0-2.5 
Rwork / Rfree  25.78/30.14 
No. atoms   
Protein  2179 
Solvent  9 
R.m.s. deviations   
Bond lengths (Å)  0.009 
Bond angles (°)  1.192 
Average isotropic B values 
(Å2) 
 47.51 
Protein  47.41 
Water  35.75 
Ramachandran 
statistics 
  
Outliers  0 
Allowed  0 
Favored  100 
Values in parentheses correspond to those in the outer resolution shell. 
Rmerge = (|(ΣI - <I>)|)/(ΣI), where <I> is the average intensity of multiple measurements. 
Rwork = Σhkl||Fobs(hkl)|| - Fcalc (hkl)||/Σhkl|Fobs(hkl)|. 
Rfree = crossvalidation R factor for 7.3% of the reflections against which the model was 
not refined. 
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3.2.3 hRock SBD is a parallel coiled coil dimer 
 The crystal structure revealed that Rock SBD is a parallel-coiled coil dimer (Fig. 18A). There 
are two dimers in the asymmetric unit that pack in a tail to tail manner. This packing interaction 
causes the coiled-coil dimer to fray at the C- terminal ends and form a four helical bundle such 
that the N-terminal half forms a dimer and the C-terminal half forms a tetramer (Fig. 18B). The 
individual chains in each dimer align with an r.m.s.d of 2.8 Å with the highest level of similarity 
at the N-terminus (Fig. 19B). The two SBD dimers structurally align with an r.m.s.d of 1.0 Å 
indicating that the two SBD dimers are essentially identical (Fig. 19A).  Since there are no major 
differences between the two dimers in the asymmetric unit the following analyses were carried 
out with the dimer composed of chains C and D. 
Analysis of the structure with the program SOCKET indicates that all the coiled coil 
interactions at the dimerization interface and at the four-helix bundle interface are canonical 
knobs into holes packing interactions [129]. Even though the interactions mediating the tetramer 
interface resemble canonical coiled-coil interactions we believe that the four helical bundle 
formed by the two dimers is an artifact of crystal packing. Using the program TWISTER, I 
determined the average pitch, rise, and radius of the overall structure to be 178.7 Å, 1.63 Å, and 
6.5 Å, respectively [130]. There is a sharp increase in the pitch where the four helices start to 
form the four-helical bundle (Fig. 20A and 20B). The rise of the coiled coil stays constant 
throughout the structure; however, there is a gradual increase in the radius of the coiled coil 
dimer from the N-termius to the C-terminus due to the helices splaying apart for the four helical 
bundle packing interaction (Fig. 20C and 20D).  These results suggest that the hRock SBD dimer 
is a traditional coiled coil dimer and any deviations observed are due to the packing interactions 
between the two dimers. 
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 Figure 19: Structure of the hRock SBD. 
(A) Ribbon diagram representing the Rock SBD parallel coiled coil dimer with Chain C in gray and Chain D in 
white. 
(B) Ribbon diagram of the two Rock SBD dimers seen in the crystal asymmetric unit. Chains C and D are shown in 
gray and white and Chains E and F are shown in green and blue. The surface entropy reduction (SER) 
mutations are shown as red spheres. The SER mutant residues lie at the interface between the two SBD dimers. 
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 Figure 20 : Structural alignment of the hRock SBD. 
(A) Structural alignment of the two SBD dimers. The two dimers align with an r.m.s.d of 1.0 Å over 70 Cα 
atoms. Alignment was done with PDB efold 
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(B) Structural alignment of the SBD monomers in each dimer. The two SBD monomers align with an r.m.s.d of 
2.8 Å over 70 Cα atoms with highest degree of difference at the C-terminus. Alignment was done with 
PDB efold. 
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 Figure 21: Analysis of the SBD coiled-coil. 
(A) Cartoon representation of the two Rock SBD dimers with Chains C and D in black and white and Chains E and 
F in green and blue. The region where the coiled coil pitch increases due the four helical bundle packing is 
highlighted in red in the C and D chains. (B) Coiled coil pitch (Å) vs. residue graph. (C) Coiled coil radius (Å) vs. 
residue graph. (D) Coiled coil rise (Å) vs. residue graph. Graphs presented in (B), (C), and (D) were calculated in 
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the program TWISTER [130]. These graphs indicate that the packing interactions between the two dimers cause the 
coiled coil dimer to fray towards the C-terminal end. 
 
 
 
 
 
3.2.4 Conserved patches in SBD that mediate the Shroom-Rock interaction 
  I took a mutational approach to identify residues in Rock SBD that mediate the Shroom-Rock 
interaction.  Using a multiple sequence alignment of 18 Rock sequences and the RISLER matrix 
in  the  ESPRIPT  program I identified and scored conserved residues in the Rock SBD [120, 
121]. Upon mapping the conserved residues on to the surface of the SBD dimer it became 
immediately apparent that while there were a number of conserved patches throughout the 
structure the N-terminal region was mostly invariant (Fig. 21A).  In collaboration with the 
Hildebrand lab I designed a series of multi-site substitution mutations that targeted the conserved 
surface exposed residues (Fig. 21B) and (Table 3). All of the targeted residues were mutated to 
alanine. The ability of these mutations to interact with hShroom SD2 domain was tested using 
gel shift and fluorescence anisotropy assays. Due to the difficulty in detecting the SD2-SBD 
complex using the minimal SBD construct (834-913) all of the mutations were made in a longer 
SBD construct (707-946) that extended into the coiled-coil region. The gel shift assays indicate 
that mutating residues in the highly conserved N-terminal patches, specifically 850QYF852 and 
857KTQ859, completely abolish SD2 binding (Fig. 22A). These observations are confirmed by the 
fluorescence anisotropy experiments (Fig. 22B). Additionally, the anisotropy experiments 
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indicate that disrupting some of the conserved residues at the C-terminus, 900ESE902, moderately 
disrupts the interaction with the SD2 domain.  Both anisotropy and gel shift assays indicate that 
the SER mutation does not disrupt the Shroom-Rock interaction (Fig. 22A and B). These results 
suggest that there are two conserved regions, one at the N-terminus and one at the C-terminus, in 
the hRock SBD that mediate the Shroom-Rock interaction with the N-terminal region playing a 
more significant role than the C-terminal region (Fig. 22C). 
 
 
 
 
 
Table 3: hRock1 Shroom binding domain mutations. 
Mutant # Residue #s Sequence 
1 850-852 QYF 
2 865-866 EE 
3 857-859 KTQ 
4 872-879 RENLKKIQ 
5 900-902 ESE 
6 906 R 
7 900-906 ESEQLAR 
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 Figure 22 : The N-terminal half of hRock SBD is highly conserved. 
(A) Surface view of the Rock SBD with the conserved residues highlighted in shades of blue. Conservation was 
obtained from a multiple sequence alignment of 16 SBD sequences and scored using the RISLER matrix in 
espript.  
(B) The conserved residues targeted for mutational analysis are highlighted in green. 
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Figure 23: Disrupting conserved residues in hRock SBD disrupts SD2 interaction. 
(A) Native gel electrophoresis with h2SD2 and wild-type or mutant hRock SBD. 10μM hShroom2 SD2 and wild-
type or mutant hRock1 SBD were mixed and incubated at room temperature prior to subjecting the protein to 
Native PAGE. 
(B) Fluorescence anisotropy of labeled hShroom2 SD2. Concentration of labeled hShroom2 SD2 was fixed at 20nM 
and increasing amounts of wild-type or mutant hRock SBD was titrated. The increase in anisotropy was 
measured at 595m. 
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(C) Surface view of the hRock SBD dimer with the conserved residues highlighted in blue. The conserved residues 
at the N-terminus that are required for SD2 interaction are highlighted in red. The conserved resides at the C-
terminus that when mutated cause a moderate defect in SD2 interaction are highlighted in orange. 
 
 
 
 
 
3.3 CONCLUSIONS 
I determined the structure of the core human Rock1 SBD spanning residues 834-913 using x-ray 
crystallography. The structure revealed that hRock SBD is a parallel coiled-coil dimer. In the 
asymmetric unit of the crystal there are two SBD dimers that pack in a tail-to-tail manner. 
Analysis of the rise, pitch, and radius of the coiled-coil with the program TWISTER indicated 
that hRock SBD is a canonical coiled-coil dimer. Upon mapping the conserved residues to the 
surface of the SBD revealed that there is a high level of conservation at the N-terminus. Using a 
combination of mutational and biochemical analysis I identified two conserved patches that play 
an important role in mediating interactions with Shroom. One of the patches is on the highly 
conserved N-terminus and the second patch is located at the C-terminus of the hRock SBD 
structure. These results suggest that conserved residues at the N- and C-terminus of SBD mediate 
interaction with Shroom. 
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4.0  CHARACTERIZATION OF THE SHROOM-ROCK COMPLEX 
4.1 INTRODUCTION 
To understand the mechanistic details of the Shroom-Rock interaction and Shroom mediated 
apical constriction we need to structurally characterize the Shroom-Rock complex. The crystal 
structures of the individual domains indicate that both SD2 and SBD are coiled coil dimers. 
Biochemical assays with the SD2 domains suggest that dimerization is important for the 
Shroom-Rock interaction [123]. Structures of other portions of the Rock coiled-coil region have 
also been determined to be coiled coil dimers [83, 84, 126]. The structure of the Rho binding 
domain of Rock in complex with RhoA indicates that Rock binds to RhoA as a dimer [84]. 
Based on these observations I can hypothesize that the SD2-SBD complex is a heterotetramer. 
To characterize the Shroom SD2-Rock SBD complex I used a series of biochemical 
assays with complexes from different species. I determined the dissociation constant of the 
Drosophila Shroom-Rock complex to be 0.58 ± 0.07 µM. Using a variety of biochemical 
techniques I was also able to determine that the molar ratio of the SD2-SBD complex is 1:1. I 
also attempted to determine the structure of the mShroom2 SD2-hRock1 SBD. Using surface 
entropy reduction mutations in both proteins I was able to obtain diffraction quality crystals. 
Upon optimization these crystals should provide high quality diffraction data that can be used to 
determine the structure of the complex using molecular replacement. 
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4.2 DROSOPHILA SHROOM-ROCK COMPLEX 
4.2.1 Fluorescence Energy Transfer 
In an effort to elucidate the molecular details of the Shroom-Rock complex, we first utilized 
fluorescence energy transfer (FRET) experiments to detect and quantify the interaction between 
dShroom and dRock SBD. These experiments were done in collaboration with Michael Trakselis 
in the Department of Chemistry at the University of Pittsburgh. We labeled dRock with Cy5 at 
its N-terminus while dShroom SD2 was labeled with Cy3 at a single cysteine (C1428) not 
believed to be located within the Rock-binding interface. There are two endogenous cysteines 
within this construct of dShroom SD2, so a conservative mutant of dShroom (C1533S) was 
generated to ensure labeling at a single position. Titration of dShroom with dRock resulted in a 
decrease in donor emission and increase in acceptor emission consistent with an increase in 
FRET due to a binding interaction. Assuming a single binding mode for this interaction, the 
equilibrium Kd is calculated to be 0.58 ± 0.07 µM (Fig. 23A).  
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 Figure 24: Characterizing the SD2-SBD complex. 
(A) Donor quenching is plotted as a function of Rock and fitted to single binding mode to give a Kd of 0.58 ± 0.07 
μM. Inset shows the decrease in donor fluorescence upon addition of different concentrations of Rock. 
(B) 5μM SBD was mixed with increasing amounts of SD2 and the resulting SD2-SBD complex was first resolved 
via Native PAGE. Bands corresponding to the complex were excised and the resulting protein eluted from the gel 
slice was resolved using SDS-PAGE. 
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4.2.2 Stoichiometry of SD2-SBD complex 
We next examined the stoichiometry of the dShroom-dRock complex. To determine this, 
purified dRock SBD and dShroom SD2 were mixed in solution to form a complex and then 
resolved on a native gel. Following electrophoresis, the complexes were excised from the gel, 
eluted, resolved by SDS-PAGE, and detected by Coomassie blue staining (Fig. 23B). 
Alternatively, purified SD2 and SBD were mixed at equimolar ratios and the complex was run 
on a gel filtration column and peak fractions were resolved by SDS-PAGE. The ratio of SD2 to 
SBD in the complex was measured by densitometry and corrected for the relative molecular 
masses of the two proteins. In all cases, isolated complexes were composed of SD2 and SBD in 
an approximately 1:1 molar ratio. While the possibility for a variety of higher-order species 
cannot be ruled out from this data, we feel that heterodimeric and heterotetrameric species are 
the most probable. I used a combination of SEC-MALS, mass spectrometry and crosslinking to 
determine if the SD2-SBD complex is a heterodimer or heterotetramer. 
4.2.2.1 Chemical Crosslinking 
Using chemical crosslinking I tried to determine the stoichiometry of the Shroom-Rock complex. 
The chemical crosslinking assay was performed with purified dShroom SD2 (1393-1576) and 
dRock SBD (724-938). Both proteins readily form dimers when exposed to small amounts of the 
crosslinker gluataraldehyde (Fig. 8A and Fig. 24). For all crosslinking experiments with the 
complex equimolar ratios of SD2 and SBD were mixed and incubated at room temperature 
before incubation with glutaraldehyde. Initial crosslinking experiments resulted in the formation 
of numerous mutlimers of varying Shroom-Rock composition that resolved as smears when 
subjected to SDS-PAGE (Fig. 25). Even after fine-tuning the crosslinking conditions I was 
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unable to resolve the SD2-SBD complex band (Fig. 26). In these crosslinking reactions the SD2 
and SBD dimer bands still readily form and can be resolved via SDS-PAGE. The reason I am 
unable to resolve a crosslinked SD2-SBD band could be because these proteins react so readily 
with the crosslinker that they form multiple crosslinked species.  
Since I was unable to resolve the complex by crosslinking dRock SBD (724-938) to 
dShroom SD2 I decided to use the minimal dRock SBD (821-938) that does not readily crosslink 
upon addition of glutaraldehyde (Fig. 27). The shorter SBD construct most likely does not 
crosslink because its reactive side chains are spaced too far apart to be crosslinked by 
glutaraldehyde. Since shorter SBD construct does not readily crosslink it is possible that the 
complex formed by this SBD and dShroomSD2 domain will be easier to resolve.  Crosslinking 
experiments with SBD (821-938) and SD2 still resulted in multiple crosslinked species; 
however, there was one distinct band of ≈ 65kDa that was not present in the SD2 alone or SBD 
alone lane (Fig. 28). This band could correspond to one SD2 dimer and one SBD dimer 
suggesting that the SD2-SBD complex is a heterotetramer. 
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 Figure 25: dRock SBD (724-938) readily dimerizes in solution. 
Purified SBD (724-938) was incubated with 0.01% glutaraldehyde for the indicated time and the resulting species 
were resolved with SDS-PAGE. 
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 Figure 26: Initial crosslinking attempt of SD2-SBD complex. 
Equimolar ratios of dShroomSD2 and dRockSBD were incubated with 0.01% glutaraldehyde for the indicated time 
and the resulting species were resolved with SDS-PAGE. The presence of various SD2-SBD multimers makes it 
difficult to resolve a single crosslinked complex band. 
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 Figure 27: Crosslinking of SD2-SBD complex does not result in a single crosslinked complex band. 
Equimolar ratios of dShroomSD2 and dRockSBD were incubated with 0.001% glutaraldehyde for the indicated time 
and the resulting species were resolved with SDS-PAGE. Fine-tuning the crosslinking conditions did not aid in 
resolving a single crosslinked complex band. 
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 Figure 28: dRock SBD (821-938) does not readily crosslink in solution with glutaraldehyde. 
Purified SBD (821-938) was incubated with 0.1% glutaraldehyde for the indicated time and the resulting species 
were resolved with SDS-PAGE. No crosslinked species was observed when dRock SBD (821-938) was subjected to 
crosslinking with glutaraldehyde. 
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 Figure 29: Crosslinking of dShroomSD2-dRock SBD (821-938). 
Equimolar ratios of dShroomSD2 and dRockSBD were incubated with 0.005% glutaraldehyde for the indicated time 
and the resulting species were resolved with SDS-PAGE. The (*) indicates the crosslinked band not seen in either 
SD2 or SBD alone lanes. This band most likely corresponds to the SD2-SBD heterotetramer. 
 
 
 
 
 
4.2.2.2 Size exclusion chromatography coupled with Multi-angle light scattering 
To confirm the crosslinking results and to determine the stoichiometry with the longer SBD 
construct I analyzed the SD2-SBD (724-938) using multi-angle light scattering. Traditional light 
scattering techniques can be used to determine the molecular mass of globular proteins that 
scatter light uniformly. Light scattering from extended or large proteins or protein complexes on 
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the other hand varies greatly depending on the angle. Therefore the extended non-globular 
structures of SD2 domain and the SBD domain make them suboptimal candidates for traditional 
light scattering experiments. Instead we decided to use multi-angle light scattering (MALS), 
which measures the scattering from various angles and can determine the molecular weight of 
molecules independent of shape. Usually MALS is coupled with size exclusion chromatography 
to ensure the measurement of a single species. Purified dShroomSD2 and dRockSBD (724-938) 
were mixed at equilmolar ratios and subjected to an initial round of gel filtration. Fractions that 
contained both proteins in equal amounts were pooled and subjected to SEC-MALS (Fig. 29A). 
The SEC-MALS results indicated that the complex eluted off the size exclusion column in one 
peak with an apparent molecular weight of ≈80kDa (Fig. 29B).  This molecular weight of the 
complex is much lower than the molecular weight for the tetramer, which would be around 
93kDa.  The molecular weight of 80kDa is slightly larger than the trimeric complex composed of 
two SBD molecules and one SD2 molecule. These results are not consistent with the results we 
previously observed. Additional experiments are required to properly analyze and interpret the 
results from SEC-MALS. 
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 Figure 30: SEC-MALS with the dShroomSD2-dRock (724-938). 
(A) Equimolar amounts of dShroom SD2-dRock SBD we mixed and subjection to a first round of gel filtration. Gel 
filtration fractions resolved by SDS-PAGE and the fractions pooled for SEC-MALS are highlighted by the 
black box. 
(B) SEC-MALS chromatogram. The complex eluted off the column in peak between 20 and 23mls with the 
apparent M.W. weight of the complex is ≈80kDa. This molecular suggests that the SD2-SBD complex is a 
heterotrimer. 
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 4.2.2.3 Mass Spectrometry 
Mass spectrometry (MS) coupled with the soft ionization processes of electrospray ionization 
(ES) can be used to detect stoichiometry of complexes. To determine if I could resolve the 
discrepancy between the results from the crosslinking and the SEC-MALS experiments I 
performed ES-MS. Once again peak gel filtrations that contain both SD2 and SBD were pooled 
and concentrated to 42μM. The concentrated protein was dialyzed into buffer containing 100mM 
ammonium acetate and 20mM Tris pH 7.0. This buffer is ideal for MS, however, the SD2-SBD 
complex is not stable for very long in these conditions (Fig. 30). All the MS-ES experiments 
were performed on the complex within one week of dialysis into the acetate buffer. The protein 
was subjected to gel filtration using a C4 column immediately prior to ionization. The major 
peaks observed from ES-MS had a molecular weight of 21kDa, 25kDa, 42kDa and 51kDa (Fig. 
31).  These molecular weights correspond to SD2 and SBD monomers and dimers. These results 
suggest that ES-MS was not a gentle enough technique to keep the SD2-SBD complex intact. 
However, the presence of both SD2 and SBD dimers could suggest that the complex is a 
heterotetramer. Crosslinking the complex prior to ionization and using an even softer ionization 
technique called nanospray ES might aid in keeping the complex intact during ES-MS. 
4.2.2.4 Crystallization of the SD2-SBD complex 
The biochemical assays described above, with the exception of SEC-MALS, suggest that 
the molecular ratio of the Shroom-Rock complex is 1:1; however, it is still unclear if the 
complex is a heterodimer or a heterotetramer. To determine the composition of the complex I 
decided to determine the crystal structure of the complex. Co-expression and co-purification 
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attempts made by the VanDemark lab and the Hildebrand lab were not successful in purifying 
the large homogenous amounts of the SD2-SBD complex required for crystallography. Since I 
was able to easily purify large amounts of the individual proteins I mixed equimolar amounts of 
individually purified SD2 and SBD to generate the complex and the set up crystallization 
screens. Crystal screens with the Drosophila SD2-SBD complex did not yield any crystals; 
however, the mouse Shroom2 SD2- human Rock1 SBD complex formed crystals.  
 
 
 
Figure 31: dShroomSD2-dRock SBD complex is not stable in the ammonium acetate buffer. 
Native PAGE to resolve the dShroomSD2-dRock SBD (724-938) complex after gel filtration and dialysis into 
ammonium acetate buffer. The peak fractions containing the SD2-SBD complex from the size exclusion column 
were pooled and subjected to native PAGE before and after dialysis into the ammonium acetate buffer. The proteins 
degrade in the ammonium acetate approximately 2 weeks after dialysis. 
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Figure 32: Electrospray-Mass Spectrometry of dShroomSD2-dRock SBD (724-938). 
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Major peaks corresponding to the dRock SBD monomer (25kDa) and dimer (51kDa) are shown in (A) and major 
peaks corresponding to the dShroom SD2 monomer (21kDa) and dimer (42kDa) are shown (B). The ES-MS 
spectrum indicate that this technique was not soft enough to keep the SD2-SBD complex intact. 
 
 
 
 
 
4.3 MOUSE SHROOM2- HUMAN ROCK1 COMPLEX 
Human Rock1 and mouse Rock1 share 96% percent identity therefore; mouse Shroom2-Human 
Rock1 complex is biologically significant (Fig. 32). Purified mShroom2 SD2 (1293-1476) and 
hRock1 SBD (834-913) mixed at equimolar ratios to concentration of 15mg/ml. The complex 
was allowed to sit at room temperature for 30min in buffer containing 100mM NaCl and 20mM 
Tris pH 8.0 before setting up crystallization trials.  The mShroom2-hRock1 complex crystallized 
at room temperature in two conditions both of which contained 15% Ethanol, 0.2 MgCl2 and 
either 0.1M Imidazole pH 8.0 or 0.1M HEPES pH 7.5. In both of these conditions the complex 
formed thin needle or rod shaped crystals that we very difficult to manipulate (Fig. 33A). I 
confirmed the presence of both proteins in the crystals by isolating the crystals and visualizing 
the proteins in them using SDS-PAGE and coomassie staining (Fig. 33B). I was able to 
crystallize the mShroom2 SD2-hRock1 SBD complex; however, the needle shaped crystals were 
difficult to optimize and manipulate. 
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 Figure 33: Pairwise alignment of SBD from mouse and human Rock1. 
Pariwise alignment of residues 834-913 from human Rock1 and mouse Rock 1. The alignment was was done using 
ClustalW and  visualized using JalView [119]. Percent identity was calculated in JalView to be 96%. 
 
 
 
 
 
 
 
Figure 34: mShroom2 SD2-hRock1 SBD crystals. 
(A) Optimized mShroom2 SD2-hRock1 SBD crystals. 
(B) Crystals were extensively washed, dissolved and visualized using SDS-PAGE and coomassie staining. These 
crystals contained both mShroom2 SD2 and hRock1 SBD proteins.  
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To improve crystal quality I decided to use surface entropy reduction mutants of both 
proteins.  Once again I mixed equimolar ratios of both the mutant SER proteins that were 
purified individually and set up crystallization trials. The SER mutant complex crystallized in 
several conditions forming mostly thick rods or plates (Fig. 34A). These crystals proved to be 
much easier to optimize and manipulate. I once again confirmed the presence of both proteins in 
the crystals using SDS-PAGE and coomassie staining (Fig. 34B). After initial rounds of 
optimization these crystals diffracted to ~ 7.5 Å. Upon further optimization these crystals should 
diffract to a higher resolution and the structure of the complex can be determined using 
molecular replacement with the structures of the SD2 domain or the SBD. 
4.4 CONCLUSIONS 
I characterized the Shroom SD2-Rock SBD complex using a variety of biochemical assays. 
These biochemical assays suggest that molar ratio of the SD2-SBD complex is 1:1. Additionally, 
the results from SEC-MALS and chemical crosslinking suggest that the stoichiometry for the 
SD2-SBD complex is 2:2 but we have not ruled out higher order complexes. The 2:2 
stoichiometric ratio of the complex would be in agreement with the results observed with the 
SD2 domain and the SBD.  
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Figure 35: SER mutant mShroom2 SD2-hRock1 SBD crystals. 
(A) Optimized SER mutant mShroom2 SD2-hRock1 SBD crystals. SER mutations significantly improved 
the quality of the complex crystals. 
(B) Crystals were extensively washed, dissolved and visualized using SDS-PAGE and coomassie staining. 
These crystals contained both mShroom2 SD2 and hRock1 SBD SER mutant proteins.  
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5.0  DISCUSSION 
I used structural and biochemical studies to gain insight into the mechanistic details of the 
Shroom-Rock interaction. First, I determined the structure of the Shroom SD2 domain. The 
crystal structure revealed that the SD2 domain is an anti-parallel coiled-coil dimer. The SD2 
domain has a novel fold composed of two short arm segments that flank a longer central body 
segment. Using mutational analysis I identified two highly conserved patches in the central body 
segment that are important for Rock interaction and Shroom-mediated apical constriction. Due to 
the anti-parallel nature of the structure these two patches lie on opposite sides of the molecule. 
Through biochemical and cell based assays I also determined that dimerization is important for 
the Shroom-Rock interaction. These results suggest that the SD2 domain interacts with Rock as a 
dimer using residues in the central coiled-coil fragment. 
The dShroom SD2 domain elutes off the size-exclusion column in two peaks, with the 
first peak accounting for the majority of the protein. The second peak consists of a smaller 
species and only accounts for approximately 9% of the protein. The protein from the first peak 
was used for the crystallographic and biochemical studies described above. The structure of the 
protein in the second peak has yet to be determined. This peak consists of a smaller species, 
possibly representing an SD2 monomer or an alternate conformation of the SD2 dimer that 
adopts a more compact fold. In an effort to differentiate between these two possibilities I 
designed mutations that cause localized disruptions to the dimerization interface. These 
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dimerization mutant proteins had unique elutions profiles that did not match wild-type peak 1 or 
peak 2. This made it difficult to interpret the exact effect of these mutations on the conformation 
of the SD2 domain. These results suggested that local perturbations at the dimerization interface 
disrupts the overall fold of the SD2 domain but does not necessarily shift the equilibrium 
towards the monomeric or smaller species. Further analysis of the protein in the second peak as 
well as the homodimerization mutant proteins is required. Techniques such as analytical 
ultracentrifugation or small-angle x-ray scattering could provide better insight into alternate 
conformations of the SD2 domain and the possible transition states between these conformations. 
I next determined the structure of the Rock Shroom binding domain (SBD). To determine 
this structure I made surface entropy reduction (SER) mutations in hRock1 SBD. Ideally, the 
residues chosen for SER mutations would not be conserved. However, due to the high degree of 
conservation in the SBD one out of the three residues mutated for SER was highly conserved. 
This mutation, however, did not affect the ability of the SBD to bind the SD2 domain. The SER 
mutant diffraction data displayed diffraction anisotropy that lowered the quality of the data and 
hindered refinement of the model. To correct for diffraction anisotropy I used ellipsoidal 
truncation to remove poorly measured reflections from the dataset. This reduced the 
completeness of the data, however; removal of the poorly measured reflections improved data 
quality and model refinement. 
The crystal structure revealed that the SBD is a parallel coiled-coil dimer. It is composed 
of a single coiled coil segment with canonical knobs into holes packing interactions at the coiled-
coil interface. Mapping conserved residues to the surface of the SBD revealed that there is a 
large patch of highly conserved residues at the N-terminus of the structure. Once again I used 
mutational analysis to identify residues in the SBD that are important for Shroom interaction. 
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Detection of the SD2-SBD complex using the core hRock1 SBD construct used for 
crystallization (834-913) proved to be difficult as I was unable to detect a shift to the complex 
band via native PAGE. Since fluorescence anisotropy experiments with the core and the longer 
SBD (707-946) constructs indicate that they both bind to the SD2 domain with comparable 
affinity, the biochemical experiments described below were performed with a larger construct of 
hRock1 SBD. Biochemical assays with the hRock1 SBD mutants indicate that mutating the 
conserved residues at the N-terminus abolishes Shroom binding. There are also conserved 
residues at the C-terminus that when mutated cause a moderate defect in Shroom binding. These 
results indicate that there are two conserved surfaces in the SBD, one at the N-terminus and one 
at the C-terminus that are important for the Shroom-Rock interaction. Also, the conserved patch 
at the N-terminus plays a more significant role in Shroom binding than the conserved patch at the 
C-terminus.  
Lastly I characterized the SD2-SBD complex using a variety of biochemical assays. 
Using FRET we determined the Kd of the SD2-SBD complex to be 0.58 μM. This affinity is 
comparable to that of RhoA, which has a reported Kd of 0.13 mM [131]. We believe the molar 
ratio of the SD2-SBD complex to be 1:1; however, it is still unclear if that corresponds to a 
heterodimer or a heterotetramer. Chemical crosslinking and mass spectrometry experiments were 
unable to provide us with a clear answer as to whether the composition of the complex is a 
heterodimer or a heterotertramer. With both of these techniques we were unable to identify a 
single species of the complex. Additionally, I performed a single SEC-MALS experiment with 
the dShroom-dRock complex to determine the molecular weight of the complex. The results 
from this experiment suggested a trimeric complex, which is not in agreement the results 
observed with crosslinking or mass spectrometry. The SEC-MALS experiment was only 
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performed on the dShroomSD2-dRock SBD complex without the inclusion of proper controls 
such as determining the profile of the individual proteins. Additionally, the dRock SBD construct 
used for this experiment was a longer construct that was prone to degradation. Repeating the 
experiment with the proper controls and a complex composed of core dRock SBD that is stable 
should give us a more reliable answer towards the molecular composition of the complex. 
Results from structural, biochemical, and cell-based studies indicate that there are two 
binding surfaces in the SD2 domain and the SBD, with clear differences in the binding surfaces. 
In the SD2 domain the residues that make up the two binding surfaces are identical and come 
from both chains. Due to the anti-parallel nature of the SD2 domain, the two patches lay on 
opposite sides of the molecule. In the SBD dimer, however, each monomer contains one binding 
patch at the N-terminus and one at the C-terminus that are not identical. Due to the placement of 
these binding surfaces in the SD2 and SBD domains it is difficult to imagine a model where they 
interact without either protein going through a conformational change. If this were to happen 
then the identical binding surfaces in Shroom would be interacting with different binding 
surfaces in Rock (Fig. 36A). Instead we propose models where the Shroom-Rock interaction 
causes a conformational change in one or both domains.  
It is possible that the Rock binding patches identified in the Shroom SD2 domain only 
interact with one of the two identified Shroom binding patches in the Rock SBD. Since, mutation 
of the N-terminal patch in the Rock SBD showed a great defect in Shroom binding than the C-
terminal patch it is likely that Shroom binds to these residues in Rock. In this scenario, the 
Shroom SD2 domain would still have to go through a conformational change such that both of 
the Rock binding patches are on the same side. The Shroom SD2 domain could bend at the 
symmetry point and position the two binding patches on either side of the Rock SBD at the N-
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terminus (Fig. 36B). This model leaves open the possibility that there might be additional Rock 
binding sites on the Shroom SD2 domain that need to be identified.  
Other possible models could involve the unraveling of either the SD2 or the SBD coiled-
coil dimers upon complex formation. If the Rock SBD coiled-coil dimer splits apart then each 
monomer could associate with the Shroom SD2 dimer on opposite sides in a manner where they 
are in an anti-parallel orientation with respect to each other. Most of the structural and 
biochemical data available for the other domains suggest that Rock is a parallel dimer and does 
not change to an anti-parallel dimer. Therefore, it is somewhat unlikely that the Rock SBD dimer 
will split apart to bind Shroom on opposite sides, however; this drastic conformational change in 
the Rock SBD could trigger the activation of the kinase domain. Instead of the Rock SBD, the 
Shroom SD2 domain could also unravel and bind Rock as two monomers. The Shroom SD2 
dimer has a large protein interface and disrupting this interface could be highly unfavorable, 
however; binding to Rock could counteract this unfavorable conformational change. 
Alternatively, the two Shroom SD2 monomers could bend at the symmetry point to take on a 
conformation similar to the SD2 half dimer and then bind to Rock. 
Further experiments that address the possibility of conformational change in both 
molecules are required. To this end structures of SD domains from vertebrate Shroom proteins 
might reveal alternate conformations of this domain. Additionally, determining the structure of 
the complex will provide us with a more definitive answer of how these two domains interact. 
We currently only have crystals from a mixed species complex (human Rock-mouse Shroom). 
Even though human Rock and mouse Rock share 96% sequence identity a complex of proteins 
from the same species would be more ideal. 
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 Figure 36: SD2-SBD interaction Models. 
Possible models for how the Shroom SD2 domain and Rock SBD interact. The dShroom SD2 dimer is shown in 
orange and gray and the hRock1 SBD dimer is shown in blue and green. A) Cartoon illustrations of dShroom SD2 
domain and hRock SBD. B) Model of the Shroom SD2-Rock SBD complex where neither domain goes through any 
conformational changes. C) Model of the Shroom SD2-Rock SBD complex where the SD2 domain goes through a 
conformational change and interacts with the N-terminal region of Rock SBD. 
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6.0  MATERIALS AND METHODS 
6.1 PROTEIN EXPRESSION AND PURIFICATION 
Coding sequences for all the Shroom SD2 domain constructs and all Rock SBD constructs were 
amplified by PCR and cloned into the bacterial expression vector pET151-D/Topo (Invitrogen). 
Protein expression was performed in codon plus BL21(DE3) E.coli cells using ZY autoinduction 
media at room temperature for ~24 hours, harvested by centrifugation, and lysed via 
homogenization in 25 mM Tris pH8.0, 500 mM NaCl, 10% glycerol, 5 mM Imidazole, 5 mM 
beta-mercaptoethanol [111]. The lysate was cleared by centrifugation at 100,000 x g.  
All of the wild-type and mutant dShroom SD2 proteins were purified by nickel affinity 
chromatography (Qiagen), followed by overnight digestion with TEV protease, a second round 
of nickel affinity purification was performed to remove the liberated His-tag, TEV protease, and 
many non-specific contaminants. Gel filtration, using a Sephacryl S-200 gel filtration column 
(GE Healthcare) was performed and peak fractions were pooled and concentrated. Wild-type 
dShroom SD2 was concentrated to 9 mg/ml in 20 mM Tris pH 8.0, 0.5 M NaCl, 8% Glycerol 
and 5 mM dithiothreitol (DTT) using a Vivaspin concentrator (Millipore) prior to crystallization. 
The purity was typically >99% as verified by SDS-PAGE.  
Purification of wild-type and mutant mouse Shroom SD2, dRock SBD (724-938) and 
willd-type and mutant human Rock SBD (834-913) was aided by the addition of an anion 
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exchange chromatography step prior to gel filtration. After gel filtration peak fractions of 
mShroom2 SD2 and hRock SBD were pooled and dialyzed into buffers more compatible for 
crystallization. Wild-type and mutant mShroom2 SD2 were concentrated to 16 mg/ml prior to 
crystallization. Wild-type and mutant hRock SBD were concentrated to 14 mg/ml prior to 
crystallization. Selenomethionine substituted dShroom SD2 and mutant hRock SBD were 
expressed using PASM media, and purification was essentially the same as the native protein 
[111]. 
6.2 MUTANT MOUSE SHROOM3, DROSOPHILA SHROOM SD2, AND HUMAN 
ROCK SBD PROTEINS 
SC and HD mutations in mShrm3 and dShrm, were made using the QuikChange Site-Directed 
Mutagenesis kit (Stratagene). The surface entropy reduction mutations in mShroom2 SD2 and all 
of the mutations in hRock SBD (707-946, and 834-913) were also made using the QuikChange 
Site-Directed Mutagenesis kit (Stratagene). All biochemical assays with wild-type, SC and HD 
proteins were performed with the indicated protein fractions from gel filtration. For mShroom3 
mutants, mutagenesis was performed on mShrm3 in the pCS2-Endolyn-Shrm3 expression 
plasmid. For in vitro expression of mShrm3 SD2 mutant proteins, the mutated sequence 
encoding amino acids 1562-1986 were cloned from the Endolyn-Shrm3 vectors in pGex-2TK for 
expression in E.coli Codon+ (RIPL) cells. Recombinant proteins were expressed and purified as 
described [7].  
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6.3 CRYSTALLIZATION OF DROSOPHILA SHROOM SD2 DOMAIN 
Single, thick rod shaped crystals were obtained for dShrm SD2 via the vapor diffusion method 
with a reservoir solution containing 0.1 M MES at pH 6.0, 1.35 M K/Na tartrate, 0.7 M sodium 
thiocynate, 11% glycerol (v/v) and 4 mM DTT. Crystals grew at 4°C in 7-10 days with a typical 
size of 80 x 40 x 500 μm, and were cryoprotected by transition of the crystal into a buffer 
containing 0.1 M MES, 1.4 M K/Na tartrate, 0.9 M sodium thiocynate, 15% glycerol and 4 mM 
DTT. The cryoprotected crystals were flash frozen under liquid nitrogen prior to data collection. 
The same procedure was used to crystallize and cryoprotect selenomethionine (SeMET) 
substituted SD2. 
6.4 CRYSTALLIZATION OF HUMAN ROCK SBD 
 103 
Initial plate clusters of crystals formed at room temperature in buffers containing 20% PEG-
8000, 0.2M Calcium Acetate, and 0.1M 2-(N-morpholino)ethanesulfonic acid  pH  6.0  or,  5% 
PEG‐3000, 30% PEG‐200 and 2-(N-morpholino)ethanesulfonic acid pH 6.0, or 30% 2-Methyl-
2,4-pentanediol, 0.1M Sodium Acetate pH 4.6, and 0.2 M CaCl2 or, 20% 2-Methyl-2,4-
pentanediol and 0.1M 2-(N-morpholino)ethanesulfonic acid  pH  5.0. Upon optimization single 
plate like crystals with a typical size of  400 x 300 x 10 μm were obtained for hRock SBD at 
22°C with a reservoir solution containing 5% PEG-3000, 30% PEG 200, 0.1 M MES pH 6.0, 
2mM DTT, 0.7% butanol. Crystals were cryoprotected by transition into a cryoprotectant buffer 
containing 7% PEG-3000, 35% PEG 200, 0.1 M MES pH 6.0, 200mM NaCl, 2mM DTT and 
20% glycerol and flash frozen under liquid nitrogen prior to data collection. 
Single bipyramidal crystals with a typical size of 300 x 80 x 40 μm were obtained for 
hRock SBD SER2 via streak seeding at 4°C with a reservoir solution containing 0.1 M Citrate 
pH 6.0, and 1.0 M ammonium sulfate. Crystals were cryoprotected by transition into a buffer 
containing 0.1 M citrate pH 6.0, 2.5 M ammonium sulfate, 0.15 M NaCl, and 20% glycerol and 
flash frozen under liquid nitrogen prior to data collection. The same procedure was used to 
crystallize and cryoprotect selenomethionine (SeMET) substituted hRock SBD SER2. 
6.5 SINGLE WAVELENGTH ANOMALOUS DISPERSION 
Without any know structural homologs to guide structural determination, I used single-
wavelength anomalous dispersion to calculate phases and obtain an electron density map. Certain 
elements such as selenium have anomalous scattering patterns at certain wavelengths that can be 
used calculate the phases for the selenium atoms. Upon calculating the phases for the selenium 
atoms, phases for the rest of the atoms in the crystals can be estimated. For this purpose I 
purified and crystallized selenomethionine substituted proteins. This was done by simply 
growing up cells expressing the SD2 or SBD construct that crystallize in PASM media [111]. 
The addition of selenomethionine did not alter the crystallization conditions therefore the 
selenomethione substituted crystals were optimized using the same conditions as the native 
crystals. Data on the selenomethionine crystals were collected at the synchrotron using x-rays 
tuned to the selenium anomalous peak wavelength.    
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6.6 STRUCTURE DETERMINATION OF DSHROOM SD2 DOMAIN 
SD2 crystals belong to space group P21212 with a = 72.6 Å, b = 85.6 Å, c = 93.0 Å. Diffraction 
data from both native and SeMET dShrm SD2 crystals were collected at beamline X25 at the 
National Synchrotron Light Source. Diffraction data integration, scaling, and merging were 
performed using HKL2000 [125]. Initial phases were estimated via the SAD method using 
SHELX C/D/E [115] which found 6 of the possible 8 selenium sites. An initial model was built 
into these experimental maps using Coot [114]. This model was then further refined against 
native data and the model improved using a combination of simulated annealing, as well as 
positional, B-factor refinement, and TLS refinement [132] within Phenix [133]. Model quality 
was monitored using MolProbity [117]. All structural images in this paper were generated using 
PyMol (W. Delano; http://). The coordinates and structure factors for the Drosophila SD2 
domain structure presented in this publication have been submitted to the PDB (www.rcsb.org) 
and assigned the identifier 3THF. 
6.7 STRUCTURE DETERMINATION OF HROCK SBD 
SBD crystals belong to space group C2 with a = 142.4 Å, b = 56.2 Å, c = 80.7 Å and α = γ = 90° 
and β = 119.2°. Analysis of the native dataset using the diffraction anisotropy server [127] 
indicated  that  it was severely anisotropic diffracting  to 2.5 Å  in  the a and c direction but 
only 3.1 Å in the b direction. Diffraction data from both native and SeMET hRock SBD SER 
mutant crystals were collected at beamline X25 at the National Synchrotron Light Source. 
Diffraction data integration, scaling, and merging were performed using HKL2000 [125]. Initial 
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phases were estimated via the SAD method at 4.0 Å using SHELX C/D/E which found all four 
possible selenium sites [115]. An initial model was built into these experimental maps using 
Coot [114]. The native dateset was subjected to ellipsoidal truncation using the diffraction 
anisotropy sever and 1231 reflections were rejected. The model was refined against this 
truncated native data and the model improved using a combination of simulated annealing, as 
well as positional, B-factor refinement, and rigid body refinement [132] within Phenix [133]. 
Model quality was monitored using MolProbity [117]. 
6.8 CHEMICAL CROSSLINKING 
For all crosslinking reactions the purified proteins were incubated with the indicated 
concentration of glutaraldehyde in a reaction buffer containing 25 mM HEPES pH 7.5, 8% 
Glycerol, 500 mM NaCl and 5 mM β-ME, with a final protein concentration of 8 μM. For the 
SD2-SBD complex crosslinking reactions the individual proteins were mixed at equimolar ratios 
and incubated at room temperature for 20 minutes prior to adding the crosslinker. At each time 
point, 20μl of the crosslinking reaction was removed and the reaction stopped with 2 μl of 1.0 M 
Tris at pH 8.0 and the sample subjected to SDS-PAGE and visualized using Coomassie blue 
staining. 
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6.9 APICAL CONSTRICTION ASSAYS 
These assays were performed by Ryan Rizaldy and Debamitra Das from the Hildebrand lab. 
MDCK cells were grown in EMEM supplemented with 10% FBS, pen/strep, and L-Glutamine. 
Apical constriction assays using Endolyn-dShrm, Endo-Shrm3, Endo-mShrm3 dlSD2, or Endo-
Shrm3 harboring SC or HD were performed and imaged as described [4]. Cells were attained 
with the following antibodies: UPT132 (1:250, rabbit anti-Shrm3, [4]), Rat anti-ZO1 (1:500, 
Chemicon), Rabbit anti-pThr18/pSer19 MLC2 (1:50, Cell Signaling).  Primary antibodies were 
detected using Alexa-488 or 568 conjugated secondary antibodies (1:400, Invitrogen). Images 
were acquired using a Biorad Radiance 2000 Laser Scanning System mounted on a Nikon E800 
microscope with 40 and 60X oil objectives and processed using either ImageJ or Photoshop. The 
fluorescent intensity of ppMLC was determined using ImageJ and was achieved by measuring 
the average fluorescent intensity of a fixed ROI at the apical surface of sub-saturated confocal 
images from expressing and non-expressing cells. Fluorescent intensity of the ROI was then 
corrected for the decrease in area of apically constricted cells (n = at least 20 cells/variant). 
Change in fluorescent intensity was then determined as the ratio of the corrected intensity of 
constricted versus non-constricted cells. 
6.10 LIMITED PROTEOLYSIS 
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Approximately 20μg  of  wild‐type  or  mutant  dShroom  SD2  proteins  were  incubated  with 
13ng of the protease Subtilisin A in a reaction buffer with 8% glycerol, 500mM NaCl, Tris 
pH 8.0 and 5mM βME.   At  each  time point 20 μl of  the proteolysis  reaction was  stopped 
with  2μl  PMSF  and  the  proteolyzed  product  was  subjected  to  SDS‐PAGE  and  visualized 
using coomassie blue staining. 
 
6.11 COMPLEX FORMATION 
For native gel electrophoresis with Drosophila proteins, a fixed concentration (5 µM) of dRock 
724-938 was mixed with increasing concentration of dShrmSD2 (1-10 µM) and incubated for 1 
hour. Samples were then loaded on 8% PAGE gels and resolved by electrophoresis at 4O C. For 
native gel electrophoresis with human proteins, a fixed concentration (10 µM) of  wild-type oro 
mutant hRock 707-946 was mixed with a fixed conentration of hShroomSD2 (10 µM). Samples 
were then loaded on 12% PAGE gels and resolved by electrophoresis at 4O C.  Proteins were 
detected with Coomassie blue. For GST pull-down assays using mShrm3, either wild type GST-
Shrm3 SD2 or SC and HD mutant versions (spanning amino acids 1562-1986) bound to beads 
were mixed with soluble, untagged mShrm3 SD2 (residues 1762-1952) or hRock1 (residues 707-
948). Complexes were washed with NETN, resuspended in SDS-PAGE sample buffer, resolved 
by SDS-PAGE, and detected using Coomassie Blue.  
6.12 FLUORESCENT LABELING OF HUMAN SHROOM2 SD2 
hShroom2 SD2 was labeled at the N-terminus with Oregon Green 488 Succinimidyl ester 
(Invitrogen) in amino labeling buffer (20 mM Hepes pH 7.4, 100 mM NaCl, 5% Glycerol ). 
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Labeling reactions included 10× molar excess of fluorophore at room temperature for 2 h. Excess 
fluorophore was removed from the samples through extensive dialysis with labeling buffer. The 
labeling efficiency was quantified using the extinction coefficient of the dye compared with the 
protein concentration determined from a standard curve using a Bradford assay and found to be 
essentially 1:1. 
 
6.13 FLUORESCENCE ANISOTROPY BINDING EXPERIMENTS 
 
These experiments were performed by Robert Bauer in the Trakselis lab in the Chemistry 
Department at the Univeristy of Pittsburgh. Fluorescence anisotropy measurements were 
performed in hShroom reaction buffer (20 mM Hepes pH 7.4, 100 mM NaCl, 5% Glycerol) 
using 20 nM of N-terminally labeled hShroom-Oregon Green 488 and increasing concentrations 
of hRock. Measurements were collected as described previously using a Floromax-3 fluorimeter 
(Horiba Jobin Yvon) [134]. Labeled proteins were excited at 496 nm and emission was 
monitored at 524 nm using 5-second integration times for three consecutive readings. The 
reported values are the average of at least three independent experiments and fit by a non-linear 
least squares analysis using Kaleidagraph (Synergy, Reading, PA) to a single binding model: 
 
݀൅ሾPሿ                                                          (1) 
where A is the amplitude, Kd is the dissociation constant and [P] is the concentration of 
the titrated protein. 
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6.14 FLUORESCENT LABELING 
These experiments were performed by Robert Bauer in the Trakselis lab in the Chemistry 
Department at the Univeristy of Pittsburgh. dShroom was labeled at the N-terminus with Alexa 
594 succinimidyl ester (Invitrogen), in amino labeling buffer (20 mM Hepes pH 7.0, 100 mM 
NaCl,  8% Glycerol), or at C1428 of the C1533S mutant with Cy3 or Cy5 maleimide (GE 
Healthcare) in cysteine labeling buffer (20 mM HEPES pH 7.6, 100 mM NaCl, 8% Glycerol). 
Small (821-938) dRock was labeled at C862 with Cy3 maleimide as above. Large dRock (724-
938) was labeled at the N-terminus with Cy5 succinimidyl ester (GE Healthsciences) in amino 
labeling buffer. All labeling reactions included 10X molar excess of fluorophore, at room 
temperature for two hours. Excess fluorophore was removed from the samples through extensive 
dialysis with labeling buffer. The labeling efficiency was quantified using the extinction 
coefficient of the dye compared to the protein concentration determined from a standard curve 
using a Bradford assay and found to be essentially 1:1.  
6.15 FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) BINDING 
EXPERIMENTS 
These experiments were performed by Robert Bauer in the Trakselis lab in the Chemistry 
Department at the Univeristy of Pittsburgh. FRET titrations were performed in dShrm reaction 
buffer, using a 50 nM of Cy3-labeled dShrm or dRok and increasing concentrations of Cy5-
labelled dRok or dShrm. Cy3 was excited at 552 nM and the donor emission maxima (563 nM) 
was corrected for dilution, normalized, and plotted as a function of protein concentration as the 
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average of three independent experiments. Fluorescence quenching (FQ) titrations were fit to a 
single binding equation: 
  (2) 
where ∆FQ is the normalized change in donor fluorescence intensity and KD is the dissociation 
constant.  
6.16 MULTIANGLE LIGHT SCATTERING AND ELECTROSPRAY MASS 
SPECTROMETRY 
Purified dShroom SD2 and dRock SBD (724-938) were mixed at equimolar ratios and subjected 
to size exclusion chromatography. Fractions from gel filtration that contained both proteins in 
equal amounts were pooled and concentrated to 40μM. Prior to ES-MS the concentrated complex 
was dialyzed into buffer containing 100mM ammonium acetate and  20mM Tris pH 7.0. ES-MS 
was performed using the Q-TOF-2 instrument in Mark Bier’s lab at Carnegie Mellon University. 
The complex was subjected to a C4 gel filtration column prior to ionization. The size exclusion 
chromatography multiangle light scattering experiments were carried out in the Gronenborn 
laboratory in the Department of Structural Biology at the University of Pittsburgh.  
6.17 ISOLATION OF COMPLEX CRYSTALS 
Wild-type and mutant mShroom2 SD2-hRock1 SBD crystals were washed with the well solution 
multiple times to remove any uncrystallized protein. The washed crystals in well solution were 
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transferred to an eppendorf tube and dissolved using SDS-PAGE loading dye and visualzed 
using SDS-PAGE and coomassie staining. 
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APPENDIX A 
STRUCTURAL CHARACTERIZATION OF THE CAC1 SUBUNIT OF CHROMATIN 
ASSOCIATION FACTOR 1 
A.1 INTRODUCTION 
In eukaryotic cells, DNA is wrapped around histones into nucleosomes to form a highly 
condensed but dynamic structure known as chromatin. Nucleosomes consist of approximately 
147bp of DNA wrapped around an octamer of histone proteins (two copies each of histones 
H2A, H2B, H3 and H4) that help condense DNA Nucleosomes are compacted to form higher 
order structures via interactions with proteins such as linker histones [135].  These higher order 
chromatin structures play a key role in stably packaging large amounts of genetic material into 
the relatively small nucleus. This compact organization however greatly limits accessibility of 
the DNA to other proteins.  Even a single nucleosome is a significant barrier for all DNA 
templated processes, including transcription, DNA repair, and recombination [136, 137].  To 
overcome this barrier all these processes require the assistance of a host of other factors such as 
histone chaperones. These regulate chromatin structure by directly binding to histones and 
mediating nucleosome assembly and transport [138].  Histone chaperones can function as 
 113 
monomers or as part of multisubunit complexes and can bind histone octamers, the H3/H4 
tetramer or the H2A/H2B tetramer [139].   
The most striking example of chromatin rearrangement occurs during replication, which 
causes global disruption of chromatin to allow the passage of replication machinery [137]. 
During replication the cell needs access to all its genetic material to not only replicate its genome 
but also to faithfully convert both genomes into an organized chromatin structure that is suitable 
for the biology of that organism [137]. After the progression of the replication fork, nucleosomes 
are assembled onto both replicated strands of DNA by histone chaperones.  This nucleosome 
assembly occurs in a step-wise fashion where a histone chaperone first deposits histone H3/H4 
dimers onto DNA, then a different chaperone adds histones H2A/H2B to complete the 
nucleosome [140]. The histone chaperone responsible for carrying out the first step in 
nucleosome assembly during replication is a three protein complex conserved from yeast to 
humans, known as chromatin assembly factor 1 (CAF) [140-142].   
CAF was identified from HeLa nuclear extracts in an assay looking for factors that had 
chromatin assembly activity coupled to DNA replication [143].  The identified complex could 
assemble correctly spaced nucleosomes preferentially on DNA undergoing replication [143].  
The CAF complex is made up of three proteins Cac1, Cac2, and Cac3 (Msi1) in yeast (p150, 
p60, p48 respectively in humans [144]). Cac1 is the largest subunit of the complex and plays a 
scaffolding role where Cac2 and Cac3 both bind Cac1 to form the CAF complex [145].  Cac2 
and Cac3 are both WD-40 domain containing proteins that are homologous over the entire length 
of the WD-40 repeats [145].  Cac3 is a member of a large group of proteins (p48 family) that is 
also part of other chromatin modifying complexes such as Nucleosome Remodeling Factor 
(NURF) and Nucleosome Remodeling and Deacetylase (NuRD) [145, 146].  Of the three 
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subunits, Cac1 is most the elusive, as it has no recognized domains. The chromatin assembly 
activity of CAF is stimulated Asf1, a monomeric chaperone for histones H3 and H4. In yeast, 
Asf1 along with newly synthesized H3 and H4 forms a complex called RCAF (Replication 
Coupling Assembly Factor) [147].  RCAF promotes the chromatin assembly activity of CAF by 
a direct interaction, conserved from yeast to humans, between Asf1 and Cac2 [147-149]. 
In humans, nucleosome assembly by the CAF complex is required for progression 
through S-phase [150], and knockdown of CAF induces programmed cell death in proliferating 
cells [151].  In yeast, deletion of CAF is not lethal but does cause severe growth defects and loss 
of silencing at telomeres and mating loci [145]. CAF has been shown to localize to replication 
foci during S phase and to interact specifically with newly synthesized histones H3/H4 [152] 
[153]. CAF mediates its preference for newly synthesized histones by an interaction between 
Cac1 and histone H3 acetylated at lysine 36, a post-translational modification associated with 
newly synthesized histones [154]. CAF is not known to bind to DNA [143], instead, through a 
conserved interaction between Cac1 and PCNA, the replication processivity factor, CAF is 
recruited to replication foci [155-157]. Yeast Cac1 contains a PCNA binding motif (residues 227 
and 234) and mutating this motif abolishes PCNA binding and the preference of CAF for newly 
replicated DNA [158]. The CAF complex is involved not only in chromatin assembly during 
DNA replication, but also in DNA repair pathways [145, 159-162], where CAF is recruited to 
damaged DNA via the interactions with PCNA and/or RecQ helicases [155, 163, 164].  CAF is 
also implicated to be important for heterochromatin formation at silenced regions of the genome 
[165]. In yeast and humans CAF interacts with proteins such as Sir1, Sas2 and HP1 that are 
involved in heterochromatin formation and epigenetic inheritance [166-170].  These interactions 
result in global changes in chromatin but their specific role nucleosome assembly is still 
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unknown [165, 171, 172].  The Cac1 subuint mediates all of these interactions, thus making it a 
central player in coordinating various functions of CAF.  
In spite of the wealth of information provided by genetic and biochemical studies on the 
various interactions with CAF very little is known about mechanism underlying CAF function.  
Since Cac1 is the central player mediating CAF interactions, determining the structure of Cac1 
will allow us to coordinate this wealth of existing data, generating testable models for 
nucleosome assembly that will be the first step towards a long-term goal of elucidating the 
mechanism of CAF function. 
A.2 RESULTS 
Numerous binding partners of Cac1 have been identified such as PCNA[158] Cac2, Cac3, 
histone H3, Sir1, Sgs1 Sas2 [151, 154, 158, 170], however the precise binding sites for most of 
these proteins have not been determined.  The binding sites for Cac2 and Cac3 have been 
mapped to the C-terminal region of Cac1 specifically, between residues 215 and 429 for Cac3 
and Cac2 [141] [158]. Yeast Cac1 (yCac1) was identified as RLF2 (Rap1p localization factor-2) 
and contains the highly charged KER and ED regions but is missing the N-terminus PEST box 
that is found in the human homolog p150 [145] (Fig 2).  Previous studies have shown that the 
KER and ED regions are required for nucleosome assembly activity but the PEST box is not 
[141].  Previous studies in the VanDemark lab have shown that full-length yCac1, by itself or in 
a co-expression system with Cac2 and Cac3, is not expressed in detectable levels from bacteria 
so we chose to go after protein fragments instead (A. VanDemark, unpublished).   
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We analyzed Cac1 primary sequence using the web-based algorithms, PSIPRED and 
DISOPRED to predict likely secondary structure elements and regions of disorder [173, 174] 
[175].  Both algorithms predict that Cac1 has distinct structured and unstructured regions, 
however the DISOPRED analysis is surprisingly different from the PSIPRED analysis (Fig 3).  
There is no functional data to support either prediction so we have a number of options to choose 
from when designing Cac1 expression constructs.  Initially I chose to use domain predictions 
from PSIPRED to guide designing our constructs for expression. In spite of the overall 
discrepancy, both algorithms predicted that the KER region of Cac1 is mostly likely 
unstructured.   
PSIPRED analysis predicts secondary structure in three distinct regions of Cac1 (residues 
1-125, 220-389, 418-606, 220-606) that we will call D1, D2, D3, NΔ220 respectively (Fig 3). All 
Cac1 fragments were cloned into the pET151-DTopo vector and transformed into codon(+) 
E.coli. Protein expression was induced via the autoinduction technique [111]. While Cac1D1 has 
only modest expression in bacteria, Cac1D2 and Cac1NΔ220 are well expressed but largely 
insoluble.  Cac1D3 however was well expressed and very soluble (Fig. 35A). Limited proteolysis 
assays indicate that this Cac1 fragment is stable and therefore is an ideal candidate for 
crystallography (Fig. 35B). Cac1D3 was purified using a combination nickel affinity, and gel 
filtration chromatography. Peak fractions from the size exclusion column were pooled and 
concentrated to 9mg/ml and used for crystallization trials. Unfortunately, this Cac1 fragment did 
not yield any crystals. Additional constructs can be designed based on DISOPRED analysis that 
might prove to be more prone to crystallization.  
In spite of its various advantages, the bacterial expression system lacks the cellular 
machinery that is sometimes required to fold and/or modify eukaryotic proteins.  Eukaryotic 
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proteins expressed in bacteria requiring post-translational modifications and/or chaperone 
assisted folding can misfold and form insoluble aggregates.  Expression of eukaryotic proteins 
particularly misfolded protein can also result in degradation.  To overcome the problems with 
expression and solubility seen with the Cac1 fragments, I choose to try to purify them using a 
yeast expression system. The yCac1 fragments described above were cloned into the galactose 
inducible yeast expression vector pTF197, which adds a 12x his-tag to the N-terminus of the 
protein that can be used to detect protein expression via Western blotting. Preliminary expression 
tests indicate that all of the Cac1 fragments express very poorly in yeast. Other eukaryotic 
protein expression systems such as the bacculovirus expression system might aid in expression 
and purification of Cac1 fragments. In fact structures of the smallest CAF subunit Cac3 has been 
determined with protein expressed from a bacculovirus expression system [146]. 
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 Figure 37: Cac1D3 expression and limited proteolysis. 
(A) Expression and solubility of Cac1D3 after cell lysis was assayed via SDS-PAGE. 
(B) Limited proteolysis of Cac1D3. Purified protein was incubated with increasing amounts of 
trypsin (0.004% - 0.5%) for 20min . The digested fragments were visualized using SDS-PAGE. 
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